Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:pyridine nucleotide
go back to main search page
Accession:CHEBI:36980 term browser browse the term
Synonyms:related_synonym: pyridine nucleotides


show annotations for term's descendants           Sort by:
NAD zwitterion term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acmsd aminocarboxymuconate semialdehyde decarboxylase increases abundance EXP ACMSD protein results in increased abundance of NAD CTD PMID:17896587 NCBI chr13:39,200,412...39,245,954
Ensembl chr13:39,200,314...39,245,209 		JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO NAD promotes the reaction [AKR1A1 protein affects the chemical synthesis of benzo(a)pyrene-7,8-dione]; NAD promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 multiple interactions ISO [AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 multiple interactions ISO [AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 multiple interactions ISO [AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein] CTD PMID:25536389 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 multiple interactions
increases activity		 ISO [ALDH1A1 protein binds to NAD] which results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; [NAD co-treated with propionaldehyde] inhibits the reaction [Acrolein results in decreased activity of ALDH1A1 protein]; ALDH1A1 protein binds to and results in increased reduction of NAD; NAD binds to and results in increased activity of ALDH1A1 protein; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH1A1 protein]
NAD results in increased activity of ALDH1A1 protein		 CTD PMID:10559215 PMID:10856427 PMID:21256123 PMID:22339434 PMID:25450233 NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961 		JBrowse link
G Aldh1b1 aldehyde dehydrogenase 1 family, member B1 multiple interactions ISO [ALDH1B1 protein co-treated with NAD] results in increased metabolism of Acetaldehyde; [ALDH1B1 protein co-treated with NAD] results in increased metabolism of propionaldehyde CTD PMID:7779080 NCBI chr 5:60,063,370...60,068,378
Ensembl chr 5:60,063,225...60,068,378 		JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member multiple interactions
affects binding
affects abundance		 ISO
EXP		 [ALDH2 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; NAD inhibits the reaction [[Ethanol co-treated with Lead] results in decreased expression of and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Ethanol results in decreased expression of and results in decreased activity of ALDH2 protein]
ALDH2 protein binds to NAD
NAD binds to ALDH2 protein
Magnesium affects the reaction [NAD binds to ALDH2 protein]
ALDH2 gene polymorphism affects the abundance of NAD; ALDH2 protein affects the abundance of NAD		 CTD PMID:10559215 PMID:15629893 PMID:15900217 PMID:21276780 PMID:22339434 More... NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521 		JBrowse link
G Aldh3a1 aldehyde dehydrogenase 3 family, member A1 multiple interactions
increases activity		 ISO [ALDH3A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NAD] results in increased oxidation of benzaldehyde
NAD results in increased activity of ALDH3A1 protein		 CTD PMID:10856427 PMID:21256123 NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681 		JBrowse link
G Aldh5a1 aldehyde dehydrogenase 5 family, member A1 multiple interactions EXP NAD binds to and affects the activity of ALDH5A1 protein CTD PMID:18926807 NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator decreases expression ISO NAD results in decreased expression of BAX protein CTD PMID:12390773 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression ISO NAD results in increased expression of BCL2 protein CTD PMID:12390773 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO NAD inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein] CTD PMID:11461765 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 		JBrowse link
G Bdh1 3-hydroxybutyrate dehydrogenase 1 multiple interactions ISO NAD binds to and results in increased activity of BDH1 protein CTD PMID:25526675 NCBI chr11:69,302,534...69,343,173
Ensembl chr11:69,302,534...69,337,671 		JBrowse link
G Bdh2 3-hydroxybutyrate dehydrogenase 2 multiple interactions ISO NAD binds to and results in increased activity of BDH2 protein CTD PMID:25526675 NCBI chr 2:223,702,410...223,723,076
Ensembl chr 2:223,702,412...223,723,072 		JBrowse link
G Bmal1 basic helix-loop-helix ARNT like 1 decreases oxidation ISO BMAL1 gene mutant form results in decreased oxidation of NAD CTD PMID:27056296 NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO NAD inhibits the reaction [Antimycin A results in increased cleavage of CASP3 protein]; NAD inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; NAD inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] CTD PMID:24040102 PMID:24491677 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Cat catalase multiple interactions ISO CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] CTD PMID:10334203 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cbr4 carbonyl reductase 4 multiple interactions ISO NAD binds to and results in increased activity of CBR4 protein CTD PMID:25526675 NCBI chr16:28,629,928...28,684,230
Ensembl chr16:28,617,224...28,645,712 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]] CTD PMID:22561310 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]] CTD PMID:22561310 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Chrna9 cholinergic receptor nicotinic alpha 9 subunit multiple interactions ISO CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr14:42,235,218...42,241,939
Ensembl chr14:42,235,226...42,242,192 		JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO [NAD results in increased abundance of Reactive Oxygen Species] which results in increased expression of CSF2 protein CTD PMID:11752025 NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199 		JBrowse link
G Cyb5b cytochrome b5 type B multiple interactions ISO [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine CTD PMID:25170804 NCBI chr19:35,062,871...35,096,741
Ensembl chr19:35,062,813...35,098,249 		JBrowse link
G Cyb5r3 cytochrome b5 reductase 3 affects binding
multiple interactions		 ISO CYB5R3 protein binds to NAD
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine		 CTD PMID:16469290 PMID:25170804 NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298 		JBrowse link
G Dcxr dicarbonyl and L-xylulose reductase multiple interactions ISO 1,2-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 1,4-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 9,10-phenanthrenequinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; [[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased reduction of Diacetyl; [DCXR protein co-treated with NAD] results in increased reduction of Xylulose; Vitamin K 3 inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin] CTD PMID:28595002 NCBI chr10:106,006,404...106,008,293 JBrowse link
G Dek DEK proto-oncogene increases oxidation ISO DEK protein results in increased oxidation of NAD CTD PMID:28558019 NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808 		JBrowse link
G Dhrs9 dehydrogenase/reductase 9 multiple interactions ISO NAD binds to and results in increased activity of DHRS9 protein CTD PMID:25526675 NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241 		JBrowse link
G Enox2 ecto-NOX disulfide-thiol exchanger 2 multiple interactions ISO [epigallocatechin gallate results in decreased activity of ENOX2 protein] which results in increased abundance of NAD; [phenoxodiol results in decreased activity of ENOX2 protein] which results in increased abundance of NAD CTD PMID:20518072 NCBI chr  X:128,270,941...128,593,074
Ensembl chr  X:128,271,074...128,593,039 		JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions
decreases abundance
increases ADP-ribosylation
increases metabolic processing		 ISO ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased abundance of NAD]; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]
nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD]
NAD results in increased ADP-ribosylation of ERCC6 protein
ERCC6 gene mutant form results in increased metabolism of NAD		 CTD PMID:25440059 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587 		JBrowse link
G Gale UDP-galactose-4-epimerase multiple interactions ISO NAD binds to and results in increased activity of GALE protein CTD PMID:25526675 NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388 		JBrowse link
G Galnt1 polypeptide N-acetylgalactosaminyltransferase 1 increases expression ISO NAD results in increased expression of GALNT1 mRNA CTD PMID:29935245 NCBI chr18:15,489,015...15,568,849
Ensembl chr18:15,489,020...15,568,245 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase multiple interactions ISO
EXP		 [GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog; Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NAD analog inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]
[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog]; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]		 CTD PMID:15788719 NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235 		JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]] CTD PMID:22561310 NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta increases abundance
multiple interactions		 ISO GSK3B protein mutant form results in increased abundance of NAD metabolite
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]		 CTD PMID:25246272 PMID:25536389 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions ISO NAD inhibits the reaction [Doxorubicin results in decreased activity of GSR protein] CTD PMID:24491677 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661 		JBrowse link
G Hadh hydroxyacyl-CoA dehydrogenase increases metabolic processing ISO HADH protein results in increased metabolism of NAD CTD PMID:10600649 NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353 		JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase multiple interactions ISO [Celecoxib co-treated with NAD] binds to HPGD protein; [Diclofenac co-treated with NAD] binds to HPGD protein; [Dinoprostone co-treated with NAD] binds to HPGD protein; [Fenoprofen co-treated with NAD] binds to HPGD protein; [Indomethacin co-treated with NAD] binds to HPGD protein; [Ketoprofen co-treated with NAD] binds to HPGD protein; [Niflumic Acid co-treated with NAD] binds to HPGD protein; [pioglitazone co-treated with NAD] binds to HPGD protein; [rosiglitazone co-treated with NAD] binds to HPGD protein; NAD binds to and results in increased activity of HPGD protein CTD PMID:25526675 NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228 		JBrowse link
G Hpse heparanase increases expression EXP NAD results in increased expression of HPSE mRNA; NAD results in increased expression of HPSE protein CTD PMID:19429930 NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010 		JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene] CTD PMID:10334203 NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions ISO [Androstane-3,17-diol co-treated with NAD] binds to HSD11B1 protein; [Disulfiram co-treated with NAD] binds to HSD11B1 protein; [Estradiol co-treated with NAD] binds to HSD11B1 protein; [Quercetin co-treated with NAD] binds to HSD11B1 protein; [Testosterone co-treated with NAD] binds to HSD11B1 protein CTD PMID:25526675 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687 		JBrowse link
G Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 increases reduction
multiple interactions		 EXP
ISO		 HSD11B2 protein results in increased reduction of NAD
Ziram inhibits the reaction [HSD11B2 protein results in increased reduction of NAD]		 CTD PMID:26859423 NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899 		JBrowse link
G Hsd17b10 hydroxysteroid (17-beta) dehydrogenase 10 multiple interactions ISO [20-hydroxycholesterol co-treated with NAD] binds to HSD17B10 protein; [Androstane-3,17-diol co-treated with NAD] binds to HSD17B10 protein; [cholest-5-en-3 beta,7 alpha-diol co-treated with NAD] binds to HSD17B10 protein; [Cholestanol co-treated with NAD] binds to HSD17B10 protein; [Pregnanolone co-treated with NAD] binds to HSD17B10 protein; [Progesterone co-treated with NAD] binds to HSD17B10 protein; NAD binds to and results in increased activity of HSD17B10 protein CTD PMID:25526675 NCBI chr  X:21,089,142...21,091,603
Ensembl chr  X:21,089,122...21,109,488 		JBrowse link
G Hsd17b11 hydroxysteroid (17-beta) dehydrogenase 11 multiple interactions ISO NAD binds to and results in increased activity of HSD17B11 protein CTD PMID:25526675 NCBI chr14:5,693,304...5,743,157
Ensembl chr14:5,711,964...5,743,161 		JBrowse link
G Hsd17b13 hydroxysteroid (17-beta) dehydrogenase 13 multiple interactions ISO NAD binds to and results in increased activity of HSD17B13 protein CTD PMID:25526675 NCBI chr14:5,751,697...5,766,809
Ensembl chr14:5,752,132...5,768,166 		JBrowse link
G Hsd17b14 hydroxysteroid (17-beta) dehydrogenase 14 multiple interactions ISO NAD binds to and results in increased activity of HSD17B14 protein CTD PMID:25526675 NCBI chr 1:96,029,224...96,039,577
Ensembl chr 1:96,029,284...96,039,883 		JBrowse link
G Hsd17b2 hydroxysteroid (17-beta) dehydrogenase 2 multiple interactions ISO NAD binds to and results in increased activity of HSD17B2 protein CTD PMID:25526675 NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202 		JBrowse link
G Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 multiple interactions ISO NAD binds to and results in increased activity of HSD17B4 protein CTD PMID:25526675 NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952 		JBrowse link
G Hsd17b6 hydroxysteroid (17-beta) dehydrogenase 6 multiple interactions ISO NAD binds to and results in increased activity of HSD17B6 protein CTD PMID:25526675 NCBI chr 7:422,466...442,008
Ensembl chr 7:422,480...442,425 		JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 multiple interactions ISO [Gossypol co-treated with NAD] binds to HSD17B8 protein CTD PMID:25526675 NCBI chr20:4,826,725...4,828,742
Ensembl chr20:4,822,026...4,828,742 		JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions ISO NAD binds to and results in increased activity of HSD3B1 protein CTD PMID:25526675 NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999 		JBrowse link
G Hsd3b2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 multiple interactions ISO NAD binds to and results in increased activity of HSD3B2 protein CTD PMID:25526675 NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852 		JBrowse link
G Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 multiple interactions ISO NAD binds to and results in increased activity of HSD3B7 protein CTD PMID:25526675 NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442 		JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions		 ISO IDH2 protein mutant form results in increased abundance of NAD; IDH2 protein mutant form results in increased abundance of NAD metabolite
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD metabolite]; Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD]		 CTD PMID:27469509 NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression
multiple interactions		 ISO NAD results in increased expression of IGFBP1 mRNA
NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]		 CTD PMID:32781018 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO 2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; [NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Bungarotoxins inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [[NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Mecamylamine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Strychnine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Insr insulin receptor multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein] CTD PMID:25536389 NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883 		JBrowse link
G Ldha lactate dehydrogenase A increases oxidation EXP LDHA protein results in increased oxidation of NAD CTD PMID:8632003 NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472 		JBrowse link
G Mir34a microRNA 34a decreases abundance
multiple interactions		 ISO MIR34A mRNA results in decreased abundance of NAD
[[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]		 CTD PMID:23834033 NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103 		JBrowse link
G Mtarc1 mitochondrial amidoxime reducing component 1 multiple interactions ISO [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; NAD affects the reaction [MTARC1 protein results in increased reduction of trimethyloxamine] CTD PMID:25170804 PMID:29856598 NCBI chr13:96,324,377...96,362,677
Ensembl chr13:96,339,757...96,397,796 		JBrowse link
G Mtarc2 mitochondrial amidoxime reducing component 2 multiple interactions ISO [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine CTD PMID:25170804 NCBI chr13:96,362,810...96,397,284 JBrowse link
G Muc2 mucin 2, oligomeric mucus/gel-forming increases expression ISO NAD results in increased expression of MUC2 mRNA CTD PMID:29935245 NCBI chr 1:196,799,494...196,831,740
Ensembl chr 1:196,799,517...196,831,756 		JBrowse link
G Nadk NAD kinase increases phosphorylation ISO NADK protein results in increased phosphorylation of NAD CTD PMID:22954684 NCBI chr 5:166,145,708...166,176,328
Ensembl chr 5:166,145,481...166,176,322 		JBrowse link
G Nadsyn1 NAD synthetase 1 multiple interactions ISO [NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD CTD PMID:12547821 NCBI chr 1:198,981,559...199,009,853
Ensembl chr 1:198,981,604...199,009,869 		JBrowse link
G Nampt nicotinamide phosphoribosyltransferase increases chemical synthesis
multiple interactions		 ISO NAMPT protein results in increased chemical synthesis of NAD
[[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [Acetaminophen results in decreased expression of NAMPT protein] which results in decreased abundance of NAD; [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased activity of NAMPT protein] which results in decreased abundance of NAD; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Niacinamide inhibits the reaction [[Acetaminophen results in decreased expression of NAMPT protein] which results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]		 CTD PMID:23834033 PMID:25505128 PMID:33949241 NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100 		JBrowse link
G Ndufs4 NADH:ubiquinone oxidoreductase subunit S4 affects abundance ISO NDUFS4 protein affects the abundance of NAD CTD PMID:21383081 NCBI chr 2:45,951,327...46,061,829
Ensembl chr 2:45,951,313...46,061,846 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases oxidation
multiple interactions		 EXP NQO1 protein results in increased oxidation of NAD
NAD promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3]		 CTD PMID:27558805 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein CTD PMID:27026705 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722 		JBrowse link
G P2ry1 purinergic receptor P2Y1 multiple interactions ISO P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 2:145,241,975...145,248,186
Ensembl chr 2:145,241,849...145,248,457 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
decreases abundance
affects abundance		 ISO
EXP		 [Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD; benzamide inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; benzamide inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]
5-chloro-2-(3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl)-4(3H)-quinazolinone inhibits the reaction [PARP1 protein results in decreased abundance of NAD]
PARP1 protein mutant form affects the abundance of NAD
[2,5,2',5'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3,4,3',4'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein; [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]; Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein]; PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; PARP1 protein promotes the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]]
PARP1 protein affects the abundance of NAD		 CTD PMID:11593040 PMID:15075382 PMID:15147502 PMID:17669606 PMID:19433264 More... NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Parp10 poly (ADP-ribose) polymerase family, member 10 decreases abundance ISO PARP10 protein results in decreased abundance of NAD CTD PMID:33051211 NCBI chr 7:107,949,031...107,958,377
Ensembl chr 7:107,949,043...107,958,304 		JBrowse link
G Pla2g6 phospholipase A2 group VI multiple interactions ISO PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 7:110,851,378...110,891,557
Ensembl chr 7:110,851,378...110,891,114 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions
decreases activity		 EXP 3-aminobenzamide inhibits the reaction [NAD results in decreased activity of PPARG protein] CTD PMID:18815186 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468 		JBrowse link
G Ppt1 palmitoyl-protein thioesterase 1 affects abundance ISO PPT1 gene mutant form affects the abundance of NAD CTD PMID:21224254 NCBI chr 5:135,121,164...135,142,048
Ensembl chr 5:135,121,163...135,142,048 		JBrowse link
G Rdh10 retinol dehydrogenase 10 multiple interactions ISO NAD binds to and results in increased activity of RDH10 protein CTD PMID:25526675 NCBI chr 5:3,186,671...3,215,572
Ensembl chr 5:3,188,445...3,215,572 		JBrowse link
G Rdh16 retinol dehydrogenase 16 multiple interactions ISO NAD binds to and results in increased activity of RDH16 protein CTD PMID:25526675 NCBI chr 7:63,616,711...63,625,053
Ensembl chr 7:63,597,536...63,624,124 		JBrowse link
G Rdh5 retinol dehydrogenase 5 multiple interactions ISO NAD binds to and results in increased activity of RDH5 protein CTD PMID:25526675 NCBI chr 7:1,341,172...1,346,863
Ensembl chr 7:1,340,934...1,351,558 		JBrowse link
G Sdr16c5 short chain dehydrogenase/reductase family 16C, member 5 affects activity
multiple interactions		 ISO NAD affects the activity of SDR16C5 protein
NAD binds to and results in increased activity of SDR16C5 protein		 CTD PMID:18926804 PMID:25526675 NCBI chr 5:17,018,813...17,043,974
Ensembl chr 5:17,018,813...17,040,970 		JBrowse link
G Sdr9c7 short chain dehydrogenase/reductase family 9C, member 7 multiple interactions ISO NAD binds to and results in increased activity of SDR9C7 protein CTD PMID:25526675 NCBI chr 7:63,703,788...63,720,325
Ensembl chr 7:63,707,071...63,721,480 		JBrowse link
G Sirt1 sirtuin 1 multiple interactions
increases response to substance
increases activity
decreases abundance		 ISO
EXP		 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]]; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; [Resveratrol results in increased abundance of NAD] which results in increased expression of SIRT1 protein; NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]
SIRT1 protein results in increased susceptibility to NAD
NAD results in increased activity of SIRT1 protein
[MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein
NAD inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]]		 CTD PMID:19288225 PMID:19928762 PMID:22561310 PMID:23834033 PMID:25536389 More... NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260 		JBrowse link
G Smpd2 sphingomyelin phosphodiesterase 2 affects activity ISO NAD affects the activity of SMPD2 protein CTD PMID:20518072 NCBI chr20:44,986,229...44,989,343
Ensembl chr20:44,986,231...44,989,441 		JBrowse link
G Sphk1 sphingosine kinase 1 decreases activity ISO NAD results in decreased activity of SPHK1 protein CTD PMID:20518072 NCBI chr10:101,758,567...101,764,240
Ensembl chr10:101,758,711...101,764,240 		JBrowse link
G Taldo1 transaldolase 1 decreases abundance ISO TALDO1 gene mutant form results in decreased abundance of NAD CTD PMID:19436114 NCBI chr 1:196,493,634...196,503,965
Ensembl chr 1:196,493,589...196,503,974 		JBrowse link
G Tgds TDP-glucose 4,6-dehydratase multiple interactions ISO NAD binds to and results in increased activity of TGDS protein CTD PMID:25526675 NCBI chr15:95,175,064...95,195,555
Ensembl chr15:95,174,608...95,195,554 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
decreases expression		 ISO [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]
NAD promotes the reaction [Acetaminophen results in decreased expression of TRP53 protein]
NAD results in decreased expression of TP53 protein		 CTD PMID:10334203 PMID:11461765 PMID:12390773 PMID:34216621 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Tyr tyrosinase multiple interactions
increases oxidation		 ISO ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]; Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD] CTD PMID:20685355 NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207 		JBrowse link
G Uxs1 UDP-glucuronate decarboxylase 1 multiple interactions ISO [thymidine 5'-diphosphate co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucuronic Acid co-treated with NAD] binds to UXS1 protein CTD PMID:25526675 NCBI chr 9:653,740...731,121
Ensembl chr 9:653,659...756,334 		JBrowse link
G Xrcc1 X-ray repair cross complementing 1 decreases reduction
multiple interactions		 ISO XRCC1 gene mutant form results in decreased reduction of NAD
[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD; olaparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; XRCC1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]]		 CTD PMID:30998386 PMID:35778544 NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701 		JBrowse link
NAD(+) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acmsd aminocarboxymuconate semialdehyde decarboxylase increases abundance EXP ACMSD protein results in increased abundance of NAD CTD PMID:17896587 NCBI chr13:39,200,412...39,245,954
Ensembl chr13:39,200,314...39,245,209 		JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO NAD promotes the reaction [AKR1A1 protein affects the chemical synthesis of benzo(a)pyrene-7,8-dione]; NAD promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 multiple interactions ISO [AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 multiple interactions ISO [AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 multiple interactions ISO [AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein] CTD PMID:25536389 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 multiple interactions
increases activity		 ISO [ALDH1A1 protein binds to NAD] which results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; [NAD co-treated with propionaldehyde] inhibits the reaction [Acrolein results in decreased activity of ALDH1A1 protein]; ALDH1A1 protein binds to and results in increased reduction of NAD; NAD binds to and results in increased activity of ALDH1A1 protein; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH1A1 protein]
NAD results in increased activity of ALDH1A1 protein		 CTD PMID:10559215 PMID:10856427 PMID:21256123 PMID:22339434 PMID:25450233 NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961 		JBrowse link
G Aldh1b1 aldehyde dehydrogenase 1 family, member B1 multiple interactions ISO [ALDH1B1 protein co-treated with NAD] results in increased metabolism of Acetaldehyde; [ALDH1B1 protein co-treated with NAD] results in increased metabolism of propionaldehyde CTD PMID:7779080 NCBI chr 5:60,063,370...60,068,378
Ensembl chr 5:60,063,225...60,068,378 		JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member multiple interactions
affects binding
affects abundance		 ISO
EXP		 [ALDH2 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; NAD inhibits the reaction [[Ethanol co-treated with Lead] results in decreased expression of and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Ethanol results in decreased expression of and results in decreased activity of ALDH2 protein]
ALDH2 protein binds to NAD
NAD binds to ALDH2 protein
Magnesium affects the reaction [NAD binds to ALDH2 protein]
ALDH2 gene polymorphism affects the abundance of NAD; ALDH2 protein affects the abundance of NAD		 CTD PMID:10559215 PMID:15629893 PMID:15900217 PMID:21276780 PMID:22339434 More... NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521 		JBrowse link
G Aldh3a1 aldehyde dehydrogenase 3 family, member A1 multiple interactions
increases activity		 ISO [ALDH3A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NAD] results in increased oxidation of benzaldehyde
NAD results in increased activity of ALDH3A1 protein		 CTD PMID:10856427 PMID:21256123 NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681 		JBrowse link
G Aldh5a1 aldehyde dehydrogenase 5 family, member A1 multiple interactions EXP NAD binds to and affects the activity of ALDH5A1 protein CTD PMID:18926807 NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator decreases expression ISO NAD results in decreased expression of BAX protein CTD PMID:12390773 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression ISO NAD results in increased expression of BCL2 protein CTD PMID:12390773 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO NAD inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein] CTD PMID:11461765 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 		JBrowse link
G Bdh1 3-hydroxybutyrate dehydrogenase 1 multiple interactions ISO NAD binds to and results in increased activity of BDH1 protein CTD PMID:25526675 NCBI chr11:69,302,534...69,343,173
Ensembl chr11:69,302,534...69,337,671 		JBrowse link
G Bdh2 3-hydroxybutyrate dehydrogenase 2 multiple interactions ISO NAD binds to and results in increased activity of BDH2 protein CTD PMID:25526675 NCBI chr 2:223,702,410...223,723,076
Ensembl chr 2:223,702,412...223,723,072 		JBrowse link
G Bmal1 basic helix-loop-helix ARNT like 1 decreases oxidation ISO BMAL1 gene mutant form results in decreased oxidation of NAD CTD PMID:27056296 NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO NAD inhibits the reaction [Antimycin A results in increased cleavage of CASP3 protein]; NAD inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; NAD inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] CTD PMID:24040102 PMID:24491677 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Cat catalase multiple interactions ISO CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] CTD PMID:10334203 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cbr4 carbonyl reductase 4 multiple interactions ISO NAD binds to and results in increased activity of CBR4 protein CTD PMID:25526675 NCBI chr16:28,629,928...28,684,230
Ensembl chr16:28,617,224...28,645,712 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]] CTD PMID:22561310 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]] CTD PMID:22561310 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Chrna9 cholinergic receptor nicotinic alpha 9 subunit multiple interactions ISO CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr14:42,235,218...42,241,939
Ensembl chr14:42,235,226...42,242,192 		JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO [NAD results in increased abundance of Reactive Oxygen Species] which results in increased expression of CSF2 protein CTD PMID:11752025 NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199 		JBrowse link
G Cyb5b cytochrome b5 type B multiple interactions ISO [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine CTD PMID:25170804 NCBI chr19:35,062,871...35,096,741
Ensembl chr19:35,062,813...35,098,249 		JBrowse link
G Cyb5r3 cytochrome b5 reductase 3 affects binding
multiple interactions		 ISO CYB5R3 protein binds to NAD
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine		 CTD PMID:16469290 PMID:25170804 NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298 		JBrowse link
G Dcxr dicarbonyl and L-xylulose reductase multiple interactions ISO 1,2-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 1,4-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 9,10-phenanthrenequinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; [[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased reduction of Diacetyl; [DCXR protein co-treated with NAD] results in increased reduction of Xylulose; Vitamin K 3 inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin] CTD PMID:28595002 NCBI chr10:106,006,404...106,008,293 JBrowse link
G Dek DEK proto-oncogene increases oxidation ISO DEK protein results in increased oxidation of NAD CTD PMID:28558019 NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808 		JBrowse link
G Dhrs9 dehydrogenase/reductase 9 multiple interactions ISO NAD binds to and results in increased activity of DHRS9 protein CTD PMID:25526675 NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241 		JBrowse link
G Enox2 ecto-NOX disulfide-thiol exchanger 2 multiple interactions ISO [epigallocatechin gallate results in decreased activity of ENOX2 protein] which results in increased abundance of NAD; [phenoxodiol results in decreased activity of ENOX2 protein] which results in increased abundance of NAD CTD PMID:20518072 NCBI chr  X:128,270,941...128,593,074
Ensembl chr  X:128,271,074...128,593,039 		JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions
decreases abundance
increases ADP-ribosylation
increases metabolic processing		 ISO ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased abundance of NAD]; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]
nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD]
NAD results in increased ADP-ribosylation of ERCC6 protein
ERCC6 gene mutant form results in increased metabolism of NAD		 CTD PMID:25440059 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587 		JBrowse link
G Gale UDP-galactose-4-epimerase multiple interactions ISO NAD binds to and results in increased activity of GALE protein CTD PMID:25526675 NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388 		JBrowse link
G Galnt1 polypeptide N-acetylgalactosaminyltransferase 1 increases expression ISO NAD results in increased expression of GALNT1 mRNA CTD PMID:29935245 NCBI chr18:15,489,015...15,568,849
Ensembl chr18:15,489,020...15,568,245 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase multiple interactions ISO
EXP		 [GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog; Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NAD analog inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]
[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog]; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]		 CTD PMID:15788719 NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235 		JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]] CTD PMID:22561310 NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta increases abundance
multiple interactions		 ISO GSK3B protein mutant form results in increased abundance of NAD metabolite
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]		 CTD PMID:25246272 PMID:25536389 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions ISO NAD inhibits the reaction [Doxorubicin results in decreased activity of GSR protein] CTD PMID:24491677 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661 		JBrowse link
G Hadh hydroxyacyl-CoA dehydrogenase increases metabolic processing ISO HADH protein results in increased metabolism of NAD CTD PMID:10600649 NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353 		JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase multiple interactions ISO [Celecoxib co-treated with NAD] binds to HPGD protein; [Diclofenac co-treated with NAD] binds to HPGD protein; [Dinoprostone co-treated with NAD] binds to HPGD protein; [Fenoprofen co-treated with NAD] binds to HPGD protein; [Indomethacin co-treated with NAD] binds to HPGD protein; [Ketoprofen co-treated with NAD] binds to HPGD protein; [Niflumic Acid co-treated with NAD] binds to HPGD protein; [pioglitazone co-treated with NAD] binds to HPGD protein; [rosiglitazone co-treated with NAD] binds to HPGD protein; NAD binds to and results in increased activity of HPGD protein CTD PMID:25526675 NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228 		JBrowse link
G Hpse heparanase increases expression EXP NAD results in increased expression of HPSE mRNA; NAD results in increased expression of HPSE protein CTD PMID:19429930 NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010 		JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene] CTD PMID:10334203 NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions ISO [Androstane-3,17-diol co-treated with NAD] binds to HSD11B1 protein; [Disulfiram co-treated with NAD] binds to HSD11B1 protein; [Estradiol co-treated with NAD] binds to HSD11B1 protein; [Quercetin co-treated with NAD] binds to HSD11B1 protein; [Testosterone co-treated with NAD] binds to HSD11B1 protein CTD PMID:25526675 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687 		JBrowse link
G Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 increases reduction
multiple interactions		 EXP
ISO		 HSD11B2 protein results in increased reduction of NAD
Ziram inhibits the reaction [HSD11B2 protein results in increased reduction of NAD]		 CTD PMID:26859423 NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899 		JBrowse link
G Hsd17b10 hydroxysteroid (17-beta) dehydrogenase 10 multiple interactions ISO [20-hydroxycholesterol co-treated with NAD] binds to HSD17B10 protein; [Androstane-3,17-diol co-treated with NAD] binds to HSD17B10 protein; [cholest-5-en-3 beta,7 alpha-diol co-treated with NAD] binds to HSD17B10 protein; [Cholestanol co-treated with NAD] binds to HSD17B10 protein; [Pregnanolone co-treated with NAD] binds to HSD17B10 protein; [Progesterone co-treated with NAD] binds to HSD17B10 protein; NAD binds to and results in increased activity of HSD17B10 protein CTD PMID:25526675 NCBI chr  X:21,089,142...21,091,603
Ensembl chr  X:21,089,122...21,109,488 		JBrowse link
G Hsd17b11 hydroxysteroid (17-beta) dehydrogenase 11 multiple interactions ISO NAD binds to and results in increased activity of HSD17B11 protein CTD PMID:25526675 NCBI chr14:5,693,304...5,743,157
Ensembl chr14:5,711,964...5,743,161 		JBrowse link
G Hsd17b13 hydroxysteroid (17-beta) dehydrogenase 13 multiple interactions ISO NAD binds to and results in increased activity of HSD17B13 protein CTD PMID:25526675 NCBI chr14:5,751,697...5,766,809
Ensembl chr14:5,752,132...5,768,166 		JBrowse link
G Hsd17b14 hydroxysteroid (17-beta) dehydrogenase 14 multiple interactions ISO NAD binds to and results in increased activity of HSD17B14 protein CTD PMID:25526675 NCBI chr 1:96,029,224...96,039,577
Ensembl chr 1:96,029,284...96,039,883 		JBrowse link
G Hsd17b2 hydroxysteroid (17-beta) dehydrogenase 2 multiple interactions ISO NAD binds to and results in increased activity of HSD17B2 protein CTD PMID:25526675 NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202 		JBrowse link
G Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 multiple interactions ISO NAD binds to and results in increased activity of HSD17B4 protein CTD PMID:25526675 NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952 		JBrowse link
G Hsd17b6 hydroxysteroid (17-beta) dehydrogenase 6 multiple interactions ISO NAD binds to and results in increased activity of HSD17B6 protein CTD PMID:25526675 NCBI chr 7:422,466...442,008
Ensembl chr 7:422,480...442,425 		JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 multiple interactions ISO [Gossypol co-treated with NAD] binds to HSD17B8 protein CTD PMID:25526675 NCBI chr20:4,826,725...4,828,742
Ensembl chr20:4,822,026...4,828,742 		JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions ISO NAD binds to and results in increased activity of HSD3B1 protein CTD PMID:25526675 NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999 		JBrowse link
G Hsd3b2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 multiple interactions ISO NAD binds to and results in increased activity of HSD3B2 protein CTD PMID:25526675 NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852 		JBrowse link
G Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 multiple interactions ISO NAD binds to and results in increased activity of HSD3B7 protein CTD PMID:25526675 NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442 		JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions		 ISO IDH2 protein mutant form results in increased abundance of NAD; IDH2 protein mutant form results in increased abundance of NAD metabolite
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD metabolite]; Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD]		 CTD PMID:27469509 NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions
increases expression		 ISO NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]
NAD results in increased expression of IGFBP1 mRNA		 CTD PMID:32781018 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO 2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; [NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Bungarotoxins inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [[NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Mecamylamine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Strychnine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Insr insulin receptor multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein] CTD PMID:25536389 NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883 		JBrowse link
G Ldha lactate dehydrogenase A increases oxidation EXP LDHA protein results in increased oxidation of NAD CTD PMID:8632003 NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472 		JBrowse link
G Mir34a microRNA 34a multiple interactions
decreases abundance		 ISO [[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD] CTD PMID:23834033 NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103 		JBrowse link
G Mtarc1 mitochondrial amidoxime reducing component 1 multiple interactions ISO [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; NAD affects the reaction [MTARC1 protein results in increased reduction of trimethyloxamine] CTD PMID:25170804 PMID:29856598 NCBI chr13:96,324,377...96,362,677
Ensembl chr13:96,339,757...96,397,796 		JBrowse link
G Mtarc2 mitochondrial amidoxime reducing component 2 multiple interactions ISO [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine CTD PMID:25170804 NCBI chr13:96,362,810...96,397,284 JBrowse link
G Muc2 mucin 2, oligomeric mucus/gel-forming increases expression ISO NAD results in increased expression of MUC2 mRNA CTD PMID:29935245 NCBI chr 1:196,799,494...196,831,740
Ensembl chr 1:196,799,517...196,831,756 		JBrowse link
G Nadk NAD kinase increases phosphorylation ISO NADK protein results in increased phosphorylation of NAD CTD PMID:22954684 NCBI chr 5:166,145,708...166,176,328
Ensembl chr 5:166,145,481...166,176,322 		JBrowse link
G Nadsyn1 NAD synthetase 1 multiple interactions ISO [NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD CTD PMID:12547821 NCBI chr 1:198,981,559...199,009,853
Ensembl chr 1:198,981,604...199,009,869 		JBrowse link
G Nampt nicotinamide phosphoribosyltransferase increases chemical synthesis
multiple interactions		 ISO NAMPT protein results in increased chemical synthesis of NAD
[[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [Acetaminophen results in decreased expression of NAMPT protein] which results in decreased abundance of NAD; [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased activity of NAMPT protein] which results in decreased abundance of NAD; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Niacinamide inhibits the reaction [[Acetaminophen results in decreased expression of NAMPT protein] which results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]		 CTD PMID:23834033 PMID:25505128 PMID:33949241 NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100 		JBrowse link
G Ndufs4 NADH:ubiquinone oxidoreductase subunit S4 affects abundance ISO NDUFS4 protein affects the abundance of NAD CTD PMID:21383081 NCBI chr 2:45,951,327...46,061,829
Ensembl chr 2:45,951,313...46,061,846 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases oxidation
multiple interactions		 EXP NQO1 protein results in increased oxidation of NAD
NAD promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3]		 CTD PMID:27558805 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein CTD PMID:27026705 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722 		JBrowse link
G P2ry1 purinergic receptor P2Y1 multiple interactions ISO P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 2:145,241,975...145,248,186
Ensembl chr 2:145,241,849...145,248,457 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
decreases abundance
affects abundance		 ISO
EXP		 [Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD; benzamide inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; benzamide inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]
PARP1 protein results in decreased abundance of NAD
5-chloro-2-(3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl)-4(3H)-quinazolinone inhibits the reaction [PARP1 protein results in decreased abundance of NAD]
PARP1 protein mutant form affects the abundance of NAD
[2,5,2',5'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3,4,3',4'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein; [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]; Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein]; PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; PARP1 protein promotes the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]]
PARP1 protein affects the abundance of NAD		 CTD PMID:11593040 PMID:15075382 PMID:15147502 PMID:17669606 PMID:19433264 More... NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Parp10 poly (ADP-ribose) polymerase family, member 10 decreases abundance ISO PARP10 protein results in decreased abundance of NAD CTD PMID:33051211 NCBI chr 7:107,949,031...107,958,377
Ensembl chr 7:107,949,043...107,958,304 		JBrowse link
G Pla2g6 phospholipase A2 group VI multiple interactions ISO PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 7:110,851,378...110,891,557
Ensembl chr 7:110,851,378...110,891,114 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma decreases activity
multiple interactions		 EXP NAD results in decreased activity of PPARG protein
3-aminobenzamide inhibits the reaction [NAD results in decreased activity of PPARG protein]		 CTD PMID:18815186 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468 		JBrowse link
G Ppt1 palmitoyl-protein thioesterase 1 affects abundance ISO PPT1 gene mutant form affects the abundance of NAD CTD PMID:21224254 NCBI chr 5:135,121,164...135,142,048
Ensembl chr 5:135,121,163...135,142,048 		JBrowse link
G Rdh10 retinol dehydrogenase 10 multiple interactions ISO NAD binds to and results in increased activity of RDH10 protein CTD PMID:25526675 NCBI chr 5:3,186,671...3,215,572
Ensembl chr 5:3,188,445...3,215,572 		JBrowse link
G Rdh16 retinol dehydrogenase 16 multiple interactions ISO NAD binds to and results in increased activity of RDH16 protein CTD PMID:25526675 NCBI chr 7:63,616,711...63,625,053
Ensembl chr 7:63,597,536...63,624,124 		JBrowse link
G Rdh5 retinol dehydrogenase 5 multiple interactions ISO NAD binds to and results in increased activity of RDH5 protein CTD PMID:25526675 NCBI chr 7:1,341,172...1,346,863
Ensembl chr 7:1,340,934...1,351,558 		JBrowse link
G Sdr16c5 short chain dehydrogenase/reductase family 16C, member 5 affects activity
multiple interactions		 ISO NAD affects the activity of SDR16C5 protein
NAD binds to and results in increased activity of SDR16C5 protein		 CTD PMID:18926804 PMID:25526675 NCBI chr 5:17,018,813...17,043,974
Ensembl chr 5:17,018,813...17,040,970 		JBrowse link
G Sdr9c7 short chain dehydrogenase/reductase family 9C, member 7 multiple interactions ISO NAD binds to and results in increased activity of SDR9C7 protein CTD PMID:25526675 NCBI chr 7:63,703,788...63,720,325
Ensembl chr 7:63,707,071...63,721,480 		JBrowse link
G Sirt1 sirtuin 1 multiple interactions
increases response to substance
increases activity
decreases abundance		 ISO
EXP		 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]]; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; [Resveratrol results in increased abundance of NAD] which results in increased expression of SIRT1 protein; NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]
SIRT1 protein results in increased susceptibility to NAD
NAD results in increased activity of SIRT1 protein
[MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein
NAD inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]]		 CTD PMID:19288225 PMID:19928762 PMID:22561310 PMID:23834033 PMID:25536389 More... NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260 		JBrowse link
G Smpd2 sphingomyelin phosphodiesterase 2 affects activity ISO NAD affects the activity of SMPD2 protein CTD PMID:20518072 NCBI chr20:44,986,229...44,989,343
Ensembl chr20:44,986,231...44,989,441 		JBrowse link
G Sphk1 sphingosine kinase 1 decreases activity ISO NAD results in decreased activity of SPHK1 protein CTD PMID:20518072 NCBI chr10:101,758,567...101,764,240
Ensembl chr10:101,758,711...101,764,240 		JBrowse link
G Taldo1 transaldolase 1 decreases abundance ISO TALDO1 gene mutant form results in decreased abundance of NAD CTD PMID:19436114 NCBI chr 1:196,493,634...196,503,965
Ensembl chr 1:196,493,589...196,503,974 		JBrowse link
G Tgds TDP-glucose 4,6-dehydratase multiple interactions ISO NAD binds to and results in increased activity of TGDS protein CTD PMID:25526675 NCBI chr15:95,175,064...95,195,555
Ensembl chr15:95,174,608...95,195,554 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
decreases expression		 ISO [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]
NAD promotes the reaction [Acetaminophen results in decreased expression of TRP53 protein]
NAD results in decreased expression of TP53 protein		 CTD PMID:10334203 PMID:11461765 PMID:12390773 PMID:34216621 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Tyr tyrosinase multiple interactions
increases oxidation		 ISO ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]; Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD] CTD PMID:20685355 NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207 		JBrowse link
G Uxs1 UDP-glucuronate decarboxylase 1 multiple interactions ISO [thymidine 5'-diphosphate co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucuronic Acid co-treated with NAD] binds to UXS1 protein CTD PMID:25526675 NCBI chr 9:653,740...731,121
Ensembl chr 9:653,659...756,334 		JBrowse link
G Xrcc1 X-ray repair cross complementing 1 decreases reduction
multiple interactions		 ISO XRCC1 gene mutant form results in decreased reduction of NAD
[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD; olaparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; XRCC1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]]		 CTD PMID:30998386 PMID:35778544 NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701 		JBrowse link
NADP zwitterion term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions ISO [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]] CTD PMID:35101544 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Ache acetylcholinesterase multiple interactions EXP [Methyl Parathion co-treated with NADP] results in decreased activity of ACHE protein CTD PMID:11684353 NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651 		JBrowse link
G Agt angiotensinogen multiple interactions
decreases abundance		 EXP Ellagic Acid inhibits the reaction [AGT protein results in decreased abundance of NADP]; Losartan inhibits the reaction [AGT protein results in decreased abundance of NADP] CTD PMID:38356441 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977 		JBrowse link
G Aif1 allograft inflammatory factor 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of AIF1 protein] CTD PMID:32057834 NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668 		JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO [AKR1A1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1A1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 PMID:21910479 NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674 		JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B1 multiple interactions
affects binding
increases activity		 ISO [AKR1B1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP binds to AKR1B1 protein binds to fidarestat
NADP results in increased activity of AKR1B1 protein		 CTD PMID:21910479 PMID:23295224 PMID:23295227 NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157 		JBrowse link
G Akr1b10 aldo-keto reductase family 1 member B10 multiple interactions
increases activity
affects binding
decreases reduction		 ISO [AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde; [AKR1B10 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B10 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP results in increased activity of AKR1B10 protein
NADP binds to AKR1B10 protein mutant form binds to fidarestat
AKR1B10 protein results in decreased reduction of NADP		 CTD PMID:17329238 PMID:19013440 PMID:21910479 PMID:23295224 PMID:23295227 NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 multiple interactions ISO [AKR1C1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1C1 protein results in increased reduction of cyclopentanone] CTD PMID:21910479 PMID:23261716 NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 multiple interactions ISO [AKR1C2 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone; NADP inhibits the reaction [AKR1C2 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C2 protein results in increased reduction of cyclopentanone]; Ursodeoxycholic Acid inhibits the reaction [[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone] CTD PMID:14672942 PMID:21910479 PMID:23261716 NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 multiple interactions ISO [AKR1C3 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; NADP inhibits the reaction [AKR1C3 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C3 protein results in increased reduction of cyclopentanone] CTD PMID:14672942 PMID:21910479 PMID:23261716 NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873 		JBrowse link
G Akr1d1 aldo-keto reductase family 1, member D1 multiple interactions ISO [AKR1D1 protein co-treated with NADP] results in increased reduction of 7 alpha-hydroxy-4-cholesten-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Aldosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of cholest-4-en-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Corticosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Cortisone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Testosterone CTD PMID:25500266 NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372 		JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Superoxides; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Superoxides; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes CTD PMID:21910479 NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909 		JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 multiple interactions ISO [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione CTD PMID:21910479 NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394 		JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member multiple interactions ISO 1-benzylimidazole inhibits the reaction [NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein]]; NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein] CTD PMID:9585485 NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521 		JBrowse link
G Aldh3a1 aldehyde dehydrogenase 3 family, member A1 multiple interactions
increases activity		 ISO [ALDH3A1 protein co-treated with NADP] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NADP] results in increased oxidation of benzaldehyde
NADP results in increased activity of ALDH3A1 protein		 CTD PMID:10856427 PMID:21256123 NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681 		JBrowse link
G Atg5 autophagy related 5 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of ATG5 protein] CTD PMID:32057834 NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209 		JBrowse link
G Bche butyrylcholinesterase multiple interactions ISO [diphenylcresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tert-butylphenyl diphenyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tri-o-cresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; naringenin inhibits the reaction [[Tritolyl Phosphates co-treated with NADP] results in decreased activity of BCHE protein] CTD PMID:23085349 NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148 		JBrowse link
G Becn1 beclin 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of BECN1 protein] CTD PMID:32057834 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742 		JBrowse link
G Cat catalase multiple interactions EXP CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein] CTD PMID:24713513 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [Genistein co-treated with NADP] binds to CBR1 protein; [Quercetin co-treated with NADP] binds to CBR1 protein; [Triclosan co-treated with NADP] binds to CBR1 protein; Curcumin inhibits the reaction [NADP metabolite binds to and results in increased activity of CBR1 protein]; NADP binds to and results in increased activity of CBR1 protein; NADP metabolite binds to and results in increased activity of CBR1 protein CTD PMID:21910479 PMID:25526675 PMID:25541467 NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393 		JBrowse link
G Cbr3 carbonyl reductase 3 multiple interactions ISO NADP binds to and results in increased activity of CBR3 protein CTD PMID:25526675 NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875 		JBrowse link
G Cd38 CD38 molecule multiple interactions ISO CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986 		JBrowse link
G Ctsb cathepsin B multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of CTSB protein] CTD PMID:32057834 NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500 		JBrowse link
G Ctsd cathepsin D multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of CTSD protein] CTD PMID:32057834 NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488 		JBrowse link
G Cyb5a cytochrome b5 type A multiple interactions ISO [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] CTD PMID:22390216 NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535
Ensembl chr18:78,202,342...78,258,535 		JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions ISO CYBB protein promotes the reaction [[Doxorubicin co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:17275678 NCBI chr  X:13,358,101...13,392,570
Ensembl chr  X:13,359,430...13,392,586 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO
EXP		 NADP promotes the reaction [CYP1A1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP1A1 protein		 CTD PMID:15720144 PMID:24713513 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO [CYP1A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with binimetinib] results in decreased activity of CYP1A2 protein; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Enoxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Resveratrol results in decreased activity of CYP1A2 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:7946932 PMID:11714871 PMID:20825217 PMID:24120545 PMID:33728909 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions ISO [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,2',4,6'-tetramethoxystilbene; [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene; alpha-naphthoflavone inhibits the reaction [[CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene]; NADP promotes the reaction [CYP1B1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]; NADP promotes the reaction [CYP1B1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 PMID:16120791 PMID:19463925 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917 		JBrowse link
G Cyp2a1 cytochrome P450, family 2, subfamily a, polypeptide 1 multiple interactions ISO [NADP co-treated with CYP2A13 protein] results in increased oxidation of 2-ethynylnaphthalene; [NADP co-treated with CYP2A13 protein] results in increased oxidation of Phenanthrenes analog; [NADP co-treated with CYP2A13 protein] results in increased oxidation of propargyl ether analog CTD PMID:27137136 NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887 		JBrowse link
G Cyp2a2 cytochrome P450, family 2, subfamily a, polypeptide 2 multiple interactions EXP [CYP2A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine CTD PMID:20825217 NCBI chr 1:82,263,833...82,289,487
Ensembl chr 1:82,263,833...82,289,487 		JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 multiple interactions EXP [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B1 protein CTD PMID:11805216 PMID:16485904 NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052 		JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of N'-nitrosonornicotine; [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B6 protein; [isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein; Mephenytoin inhibits the reaction [[isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein] CTD PMID:11805216 PMID:16485904 PMID:25500267 PMID:32672941 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 multiple interactions ISO [2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein; [CYP2C19 protein co-treated with NADP] results in increased metabolism of Oxymetazoline; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Docosahexaenoic Acids co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Eicosapentaenoic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Linoleic Acid co-treated with NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ticlopidine inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:16978661 PMID:21177487 PMID:24120545 PMID:36332690 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596 		JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 multiple interactions ISO [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:24120545
G Cyp2d2 cytochrome P450, family 2, subfamily d, polypeptide 2 multiple interactions EXP [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein; CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein] CTD PMID:24713513 NCBI chr 7:113,935,138...113,939,209
Ensembl chr 7:113,935,138...113,939,209 		JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 multiple interactions ISO [CYP2D6 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP deficiency inhibits the reaction [notopterol results in decreased activity of CYP2D6 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:20825217 PMID:24120545 PMID:32198085 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO
EXP		 [vinyl carbamate co-treated with NADP] inhibits the reaction [CYP2E1 protein results in decreased methylation of Dimethylnitrosamine]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2E1 protein		 CTD PMID:11181492 PMID:24713513 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023 		JBrowse link
G Cyp2j4 cytochrome P450, family 2, subfamily j, polypeptide 4 multiple interactions ISO NADP promotes the reaction [azelnidipine results in decreased activity of CYP2J2 protein]; NADP promotes the reaction [Felodipine results in decreased activity of CYP2J2 protein] CTD PMID:30965050 NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions EXP
ISO		 [CYP3A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine
[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone; [[CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 1,4-dihydroxy-2-nonene; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone; [CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of and results in increased oxidation of 4-hydroxy-2-nonenal; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [NADP co-treated with CYP3A4 protein] results in increased activity of imidacloprid analog; [NADP co-treated with CYP3A4 protein] results in increased activity of Thiamethoxam; [retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; Dextromethorphan inhibits the reaction [[retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ketoconazole inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine]; Protons inhibits the reaction [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]		 CTD PMID:16153789 PMID:19818743 PMID:20825217 PMID:21766881 PMID:22390216 More... NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 multiple interactions EXP [CYP3A23-3A1 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine CTD PMID:20825217 NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030 		JBrowse link
G Cyp3a62 cytochrome P450, family 3, subfamily a, polypeptide 62 multiple interactions EXP [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP3A62 protein CTD PMID:24713513 NCBI chr12:16,397,998...16,433,833
Ensembl chr12:16,397,998...16,433,833 		JBrowse link
G Dcxr dicarbonyl and L-xylulose reductase multiple interactions ISO [2,6-dimethyl-1,4-benzoquinone co-treated with NADP] binds to DCXR protein; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [DCXR protein co-treated with NADP] results in increased reduction of Diacetyl; [DCXR protein co-treated with NADP] results in increased reduction of Xylulose; [Disulfiram co-treated with NADP] binds to DCXR protein; [Vitamin K 3 co-treated with NADP] binds to DCXR protein; Butyric Acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; Heptanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; hexanoic acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; NADP binds to and results in increased activity of DCXR protein; Pentanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl] CTD PMID:21910479 PMID:25526675 PMID:28595002 NCBI chr10:106,006,404...106,008,293 JBrowse link
G Decr1 2,4-dienoyl-CoA reductase 1 multiple interactions ISO NADP binds to and results in increased activity of DECR1 protein CTD PMID:25526675 NCBI chr 5:29,411,172...29,439,054
Ensembl chr 5:29,411,172...29,439,018 		JBrowse link
G Decr2 2,4-dienoyl-CoA reductase 2 multiple interactions ISO NADP binds to and results in increased activity of DECR2 protein CTD PMID:25526675 NCBI chr10:15,104,907...15,113,281
Ensembl chr10:15,002,926...15,118,479 		JBrowse link
G Dhfr dihydrofolate reductase decreases activity ISO NADP analog results in decreased activity of DHFR protein CTD PMID:22954684 NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713 		JBrowse link
G Dhrs1 dehydrogenase/reductase 1 multiple interactions ISO NADP binds to and results in increased activity of DHRS1 protein CTD PMID:25526675 NCBI chr15:29,236,522...29,243,807
Ensembl chr15:29,236,522...29,243,838 		JBrowse link
G Dhrs11 dehydrogenase/reductase 11 multiple interactions ISO NADP binds to and results in increased activity of DHRS11 protein CTD PMID:25526675 NCBI chr10:69,698,214...69,708,294
Ensembl chr10:69,698,214...69,708,295 		JBrowse link
G Dhrs13 dehydrogenase/reductase 13 multiple interactions ISO NADP binds to and results in increased activity of DHRS13 protein CTD PMID:25526675 NCBI chr10:62,920,791...62,925,952 JBrowse link
G Dhrs2 dehydrogenase/reductase 2 multiple interactions ISO [NADP co-treated with DHRS2 protein] affects the metabolism of 1-phenyl-1,2-propanedione; [NADP co-treated with DHRS2 protein] affects the metabolism of diethylglyoxime; [NADP co-treated with DHRS2 protein] affects the metabolism of Ketones; NADP binds to and results in increased activity of DHRS2 protein CTD PMID:16685466 PMID:25526675 NCBI chr15:28,688,881...28,703,646
Ensembl chr15:28,688,940...28,703,644 		JBrowse link
G Dhrs3 dehydrogenase/reductase 3 multiple interactions
increases activity		 ISO NADP binds to and results in increased activity of DHRS3 protein
NADP results in increased activity of DHRS3 protein		 CTD PMID:25451588 PMID:25526675 NCBI chr 5:156,747,939...156,782,420
Ensembl chr 5:156,747,962...156,782,417 		JBrowse link
G Dhrs4 dehydrogenase/reductase 4 multiple interactions ISO NADP binds to and results in increased activity of DHRS4 protein CTD PMID:25526675 NCBI chr15:28,966,544...28,978,135
Ensembl chr15:28,966,553...28,978,127 		JBrowse link
G Dhrs7 dehydrogenase/reductase 7 multiple interactions ISO NADP binds to and results in increased activity of DHRS7 protein CTD PMID:25526675 NCBI chr 6:91,332,259...91,347,856
Ensembl chr 6:91,251,323...91,347,892 		JBrowse link
G Dhrs7b dehydrogenase/reductase 7B multiple interactions ISO NADP binds to and results in increased activity of DHRS7B protein CTD PMID:25526675 NCBI chr10:45,504,344...45,537,094
Ensembl chr10:45,504,426...45,537,076 		JBrowse link
G Dhrs7c dehydrogenase/reductase 7C multiple interactions ISO NADP binds to and results in increased activity of DHRS7C protein CTD PMID:25526675 NCBI chr10:52,495,262...52,513,338
Ensembl chr10:52,495,262...52,513,338 		JBrowse link
G Far1 fatty acyl CoA reductase 1 multiple interactions ISO NADP binds to and results in increased activity of FAR1 protein CTD PMID:25526675 NCBI chr 1:167,644,622...167,705,868
Ensembl chr 1:167,644,677...167,705,730 		JBrowse link
G Far2 fatty acyl CoA reductase 2 multiple interactions ISO NADP binds to and results in increased activity of FAR2 protein CTD PMID:25526675 NCBI chr 4:180,973,968...181,087,862
Ensembl chr 4:181,007,622...181,087,255 		JBrowse link
G Faslg Fas ligand multiple interactions ISO CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215 		JBrowse link
G Fasn fatty acid synthase multiple interactions ISO NADP binds to and results in increased activity of FASN protein CTD PMID:25526675 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261 		JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO
EXP		 [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-aminophenol; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoro-N-methylaniline metabolite; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoroaniline; [[FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline
[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline; Methimazole inhibits the reaction [[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol]		 CTD PMID:20369854 NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647 		JBrowse link
G G6pd glucose-6-phosphate dehydrogenase increases reduction
increases expression		 ISO
EXP		 G6PD protein results in increased reduction of NADP
NADP results in increased expression of G6PD protein		 CTD PMID:1922005 PMID:5432368 NCBI chr  X:152,201,081...152,220,863
Ensembl chr  X:152,201,098...152,220,801 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase multiple interactions ISO NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] CTD PMID:15788719 NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235 		JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of GFAP protein] CTD PMID:32057834 NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589 		JBrowse link
G Gfus GDP-L-fucose synthase multiple interactions ISO NADP binds to and results in increased activity of GFUS protein CTD PMID:25526675 NCBI chr 7:107,612,087...107,617,005
Ensembl chr 7:107,612,094...107,616,948 		JBrowse link
G Glud1 glutamate dehydrogenase 1 multiple interactions ISO [GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]; dipicolinic acid inhibits the reaction [[GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]] CTD PMID:26639393 NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957 		JBrowse link
G Gmds GDP-mannose 4, 6-dehydratase multiple interactions ISO NADP binds to and results in increased activity of GMDS protein CTD PMID:25526675 NCBI chr17:32,095,315...32,621,975
Ensembl chr17:32,095,386...32,621,961 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta increases abundance ISO GSK3B protein mutant form results in increased abundance of NADP metabolite CTD PMID:25246272 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions
increases oxidation		 ISO
EXP		 NADP affects the reaction [benzyl isothiocyanate results in decreased activity of GSR protein]; NADP affects the reaction [Carmustine results in decreased activity of GSR protein]
GSR protein results in increased oxidation of NADP
caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]]; Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]
Acetylcysteine inhibits the reaction [arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]]; arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]; Potassium Dichromate promotes the reaction [GSR protein results in increased oxidation of NADP]		 CTD PMID:17937621 PMID:19167472 PMID:19668867 PMID:22036979 PMID:24634002 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions
increases reduction
increases oxidation		 ISO
EXP		 NADP binds to and results in increased activity of HSD11B1 protein
HSD11B1 protein results in increased reduction of NADP
Ziram inhibits the reaction [HSD11B1 protein results in increased oxidation of NADP]		 CTD PMID:25526675 PMID:26859423 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687 		JBrowse link
G Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 multiple interactions ISO NADP binds to and results in increased activity of HSD11B2 protein CTD PMID:25526675 NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899 		JBrowse link
G Hsd17b1 hydroxysteroid (17-beta) dehydrogenase 1 multiple interactions ISO [HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone; coumarin analog inhibits the reaction [[HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone]; NADP binds to and results in increased activity of HSD17B1 protein CTD PMID:21232530 PMID:25526675 NCBI chr10:86,009,728...86,011,928
Ensembl chr10:86,009,728...86,011,927 		JBrowse link
G Hsd17b12 hydroxysteroid (17-beta) dehydrogenase 12 multiple interactions ISO NADP binds to and results in increased activity of HSD17B12 protein CTD PMID:25526675 NCBI chr 3:79,990,048...80,113,556
Ensembl chr 3:79,990,056...80,113,617 		JBrowse link
G Hsd17b3 hydroxysteroid (17-beta) dehydrogenase 3 multiple interactions EXP
ISO		 NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]
NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]; NADP binds to and results in increased activity of HSD17B3 protein		 CTD PMID:20522127 PMID:25526675 NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554 		JBrowse link
G Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 multiple interactions ISO NADP binds to and results in increased activity of HSD17B7 protein CTD PMID:25526675 NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017 		JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 multiple interactions ISO NADP binds to and results in increased activity of HSD17B8 protein CTD PMID:25526675 NCBI chr20:4,826,725...4,828,742
Ensembl chr20:4,822,026...4,828,742 		JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions ISO [Carbenoxolone co-treated with NADP] binds to HSD3B1 protein; [Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein; [Vitamin K 3 co-treated with NADP] binds to HSD3B1 protein CTD PMID:25526675 NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999 		JBrowse link
G Hsdl1 hydroxysteroid dehydrogenase like 1 multiple interactions ISO NADP binds to and results in increased activity of HSDL1 protein CTD PMID:25526675 NCBI chr19:47,615,794...47,631,892
Ensembl chr19:47,615,796...47,631,846 		JBrowse link
G Hsdl2 hydroxysteroid dehydrogenase like 2 multiple interactions ISO [22-hydroxycholesterol co-treated with NADP] binds to HSDL2 protein; [decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; [Estradiol co-treated with NADP] binds to HSDL2 protein; [lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; NADP binds to and results in increased activity of HSDL2 protein CTD PMID:25526675 NCBI chr 5:74,443,933...74,479,104
Ensembl chr 5:74,443,872...74,479,839 		JBrowse link
G Htatip2 HIV-1 Tat interactive protein 2 multiple interactions ISO NADP binds to and results in increased activity of HTATIP2 protein CTD PMID:25526675 NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629 		JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions		 ISO IDH2 protein mutant form results in increased abundance of NADP
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NADP]		 CTD PMID:27469509 NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025 		JBrowse link
G Ins1 insulin 1 multiple interactions EXP [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:20457604 NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536 		JBrowse link
G Iyd iodotyrosine deiodinase increases oxidation ISO IYD protein results in increased oxidation of NADP CTD PMID:33352258 NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319 		JBrowse link
G Kcnab2 potassium voltage-gated channel subfamily A regulatory beta subunit 2 affects binding
multiple interactions		 EXP NADP binds to KCNAB2 protein
[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxycyclopentenone)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxyisoprostane-E2)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-arachidonyl-3-phosphorylcholine metabolite		 CTD PMID:19013139 PMID:21296056 NCBI chr 5:162,899,511...162,988,057
Ensembl chr 5:162,901,896...162,988,243 		JBrowse link
G Kdsr 3-ketodihydrosphingosine reductase multiple interactions ISO NADP binds to and results in increased activity of KDSR protein CTD PMID:25526675 NCBI chr13:22,862,117...22,894,118
Ensembl chr13:22,862,117...22,894,108 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 affects abundance ISO KEAP1 protein affects the abundance of NADP CTD PMID:21775727 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862 		JBrowse link
G Lamp1 lysosomal-associated membrane protein 1 multiple interactions ISO NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]] CTD PMID:33359019 NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of MAP1LC3B protein modified form] CTD PMID:32057834 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Mat2b methionine adenosyltransferase 2 non-catalytic beta subunit multiple interactions ISO [Resveratrol co-treated with NADP] binds to MAT2B protein; NADP binds to and results in increased activity of MAT2B protein CTD PMID:25526675 NCBI chr10:25,106,928...25,122,982
Ensembl chr10:25,106,930...25,122,777 		JBrowse link
G Nadk NAD kinase multiple interactions ISO [3-(1-deoxyribofuranosyl)benzamide results in decreased activity of NADK protein] which results in decreased abundance of NADP CTD PMID:22954684 NCBI chr 5:166,145,708...166,176,328
Ensembl chr 5:166,145,481...166,176,322 		JBrowse link
G Nat1 N-acetyltransferase 1 multiple interactions ISO [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr16:22,218,217...22,238,516
Ensembl chr16:22,208,194...22,238,520 		JBrowse link
G Nat2 N-acetyltransferase 2 multiple interactions ISO [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] CTD PMID:20545351 NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 affects abundance
affects oxidation		 ISO NFE2L2 protein affects the abundance of NADP
NFE2L2 protein affects the oxidation of NADP		 CTD PMID:21775727 PMID:29950142 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nmral1 NmrA like redox sensor 1 multiple interactions ISO [Niflumic Acid co-treated with NADP] binds to NMRAL1 protein; [Triclosan co-treated with NADP] binds to NMRAL1 protein; NADP binds to and results in increased activity of NMRAL1 protein CTD PMID:25526675 NCBI chr10:10,841,693...10,850,199
Ensembl chr10:10,841,799...10,850,192 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO
EXP		 [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes
NADP promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3]		 CTD PMID:20545351 PMID:21910479 PMID:27558805 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Nsdhl NAD(P) dependent steroid dehydrogenase-like multiple interactions ISO NADP binds to and results in increased activity of NSDHL protein CTD PMID:25526675 NCBI chr  X:150,775,034...150,807,161
Ensembl chr  X:150,775,080...150,807,142 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP] CTD PMID:17669606 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pecr peroxisomal trans-2-enoyl-CoA reductase multiple interactions ISO [Acyl Coenzyme A co-treated with NADP] binds to PECR protein; [decanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [lauroyl-coenzyme A co-treated with NADP] binds to PECR protein; NADP binds to and results in increased activity of PECR protein CTD PMID:25526675 NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511 		JBrowse link
G Pgd phosphogluconate dehydrogenase increases expression EXP NADP results in increased expression of PGD protein CTD PMID:1922005 NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778 		JBrowse link
G Por cytochrome p450 oxidoreductase multiple interactions
increases metabolic processing		 EXP
ISO		 NADP affects the reaction [POR protein affects the metabolism of Nitrofurantoin]; NADP promotes the reaction [POR protein results in increased reduction of Vitamin K 3]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP
diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP; [POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [POR protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [POR protein co-treated with NADP] results in increased chemical synthesis of Hydrogen Peroxide; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of Oxygen]; NADP promotes the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of Oxygen]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]		 CTD PMID:18206659 PMID:20545351 PMID:20561902 PMID:21215309 PMID:22390216 More... NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245 		JBrowse link
G Ppif peptidylprolyl isomerase F multiple interactions EXP [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein] CTD PMID:26975474 NCBI chr16:1,257,197...1,263,919
Ensembl chr16:1,257,106...1,263,913 		JBrowse link
G Prnp prion protein multiple interactions ISO [NADP co-treated with cupric chloride] promotes the reaction [PRNP protein binds to PRNP protein]
[Copper co-treated with NADP] promotes the reaction [PRNP protein binds to PRNP protein]; [Copper co-treated with NADP] results in increased susceptibility to [PRNP protein binds to PRNP protein]		 CTD PMID:16990274 PMID:19149680 NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937 		JBrowse link
G Ptgr1 prostaglandin reductase 1 multiple interactions EXP [PTGR1 protein co-treated with NADP] affects the reduction of (2E)-decenal; [PTGR1 protein co-treated with NADP] affects the reduction of 1-pentene-3-one; [PTGR1 protein co-treated with NADP] affects the reduction of 2,4-nonadienal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-butenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-octenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-pentenal; [PTGR1 protein co-treated with NADP] affects the reduction of 3-buten-2-one; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of Acrolein; [PTGR1 protein co-treated with NADP] affects the reduction of benzylideneacetone; [PTGR1 protein co-treated with NADP] affects the reduction of Chalcone; [PTGR1 protein co-treated with NADP] affects the reduction of cinnamaldehyde; [PTGR1 protein co-treated with NADP] results in increased reduction of and results in increased activity of acylfulvene CTD PMID:11524419 PMID:21939268 NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666 		JBrowse link
G Qdpr quinoid dihydropteridine reductase multiple interactions ISO NADP binds to and results in increased activity of QDPR protein CTD PMID:25526675 NCBI chr14:65,670,251...65,683,853
Ensembl chr14:65,670,131...65,683,854 		JBrowse link
G Rdh11 retinol dehydrogenase 11 multiple interactions ISO NADP binds to and results in increased activity of RDH11 protein CTD PMID:25526675 NCBI chr 6:97,979,377...97,995,252
Ensembl chr 6:97,979,378...97,995,252 		JBrowse link
G Rdh12 retinol dehydrogenase 12 multiple interactions ISO NADP binds to and results in increased activity of RDH12 protein CTD PMID:25526675 NCBI chr 6:98,015,465...98,028,388
Ensembl chr 6:98,015,465...98,028,388 		JBrowse link
G Rdh13 retinol dehydrogenase 13 multiple interactions ISO NADP binds to and results in increased activity of RDH13 protein CTD PMID:25526675 NCBI chr 1:69,373,014...69,401,454
Ensembl chr 1:69,373,113...69,400,908 		JBrowse link
G Rdh14 retinol dehydrogenase 14 multiple interactions ISO NADP binds to and results in increased activity of RDH14 protein CTD PMID:25526675 NCBI chr 6:33,156,569...33,161,712
Ensembl chr 6:33,156,569...33,161,712 		JBrowse link
G Rdh8 retinol dehydrogenase 8 multiple interactions ISO NADP binds to and results in increased activity of RDH8 protein CTD PMID:25526675 NCBI chr 8:19,353,191...19,360,462
Ensembl chr 8:19,353,191...19,360,462 		JBrowse link
G Sdr39u1 short chain dehydrogenase/reductase family 39U, member 1 multiple interactions ISO NADP binds to and results in increased activity of SDR39U1 protein CTD PMID:25526675 NCBI chr15:29,378,156...29,380,989
Ensembl chr15:29,378,026...29,381,560 		JBrowse link
G Sdr42e1 short chain dehydrogenase/reductase family 42E, member 1 multiple interactions ISO NADP binds to and results in increased activity of SDR42E1 protein CTD PMID:25526675 NCBI chr19:45,715,366...45,727,901
Ensembl chr19:45,715,399...45,727,901 		JBrowse link
G Spr sepiapterin reductase multiple interactions ISO NADP binds to and results in increased activity of SPR protein CTD PMID:25526675 NCBI chr 4:117,671,948...117,676,292
Ensembl chr 4:117,671,949...117,675,678 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in decreased expression of SQSTM1 protein] CTD PMID:32057834 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 multiple interactions ISO [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562 		JBrowse link
G Taldo1 transaldolase 1 decreases abundance
multiple interactions		 ISO TALDO1 gene mutant form results in decreased abundance of NADP
Acetylcysteine inhibits the reaction [TALDO1 gene mutant form results in decreased abundance of NADP]		 CTD PMID:19436114 NCBI chr 1:196,493,634...196,503,965
Ensembl chr 1:196,493,589...196,503,974 		JBrowse link
G Tdo2 tryptophan 2,3-dioxygenase affects abundance EXP TDO2 protein affects the abundance of NADP CTD PMID:7306070 NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511 		JBrowse link
G Tigar TP53 induced glycolysis regulatory phosphatase multiple interactions
increases abundance		 EXP
ISO		 NADP inhibits the reaction [Kainic Acid results in decreased expression of TIGAR protein]
NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]
TIGAR protein results in increased abundance of NADP		 CTD PMID:32057834 PMID:33359019 NCBI chr 4:159,927,136...159,946,077
Ensembl chr 4:159,927,139...159,946,029 		JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO NADP promotes the reaction [sodium bichromate results in increased expression of TP53 protein] CTD PMID:10942736 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Txn1 thioredoxin 1 multiple interactions EXP [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:20457604 NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629 		JBrowse link
G Txnrd1 thioredoxin reductase 1 multiple interactions
increases reduction		 ISO
EXP		 [NADP co-treated with Mechlorethamine] results in decreased activity of TXNRD1 protein; NADP affects the reaction [benzyl isothiocyanate results in decreased activity of TXNRD1 protein]
NADP results in increased reduction of TXNRD1 protein
[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein; [NADP co-treated with Mechlorethamine] promotes the reaction [TXNRD1 protein binds to TXNRD1 protein]; [NADP co-treated with Mechlorethamine] results in decreased activity of and results in increased alkylation of TXNRD1 protein; [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; [Sodium Selenite co-treated with NADP] inhibits the reaction [Mercuric Chloride results in decreased activity of TXNRD1 protein]; [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; [TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein]; Auranofin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dinitrochlorobenzene promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dithionitrobenzoic Acid inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; formic acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Glutathione inhibits the reaction [[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; NADP affects the reaction [arsenic trioxide results in decreased activity of TXNRD1 protein]; Oxygen deficiency inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Pentetic Acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Sodium Selenite inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]		 CTD PMID:17640917 PMID:17937621 PMID:20457604 PMID:20810785 PMID:22694104 More... NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863 		JBrowse link
G Wwox WW domain-containing oxidoreductase multiple interactions ISO NADP binds to and results in increased activity of WWOX protein CTD PMID:25526675 NCBI chr19:42,432,141...43,360,278
Ensembl chr19:42,432,152...43,359,391 		JBrowse link
NADP(+) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions ISO [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]] CTD PMID:35101544 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Ache acetylcholinesterase multiple interactions EXP [Methyl Parathion co-treated with NADP] results in decreased activity of ACHE protein CTD PMID:11684353 NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651 		JBrowse link
G Agt angiotensinogen multiple interactions
decreases abundance		 EXP Ellagic Acid inhibits the reaction [AGT protein results in decreased abundance of NADP]; Losartan inhibits the reaction [AGT protein results in decreased abundance of NADP] CTD PMID:38356441 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977 		JBrowse link
G Aif1 allograft inflammatory factor 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of AIF1 protein] CTD PMID:32057834 NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668 		JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO [AKR1A1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1A1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 PMID:21910479 NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674 		JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B1 multiple interactions
increases activity
affects binding		 ISO [AKR1B1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP results in increased activity of AKR1B1 protein
NADP binds to AKR1B1 protein binds to fidarestat		 CTD PMID:21910479 PMID:23295224 PMID:23295227 NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157 		JBrowse link
G Akr1b10 aldo-keto reductase family 1 member B10 multiple interactions
increases activity
affects binding
decreases reduction		 ISO [AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde; [AKR1B10 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B10 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP results in increased activity of AKR1B10 protein
NADP binds to AKR1B10 protein mutant form binds to fidarestat
AKR1B10 protein results in decreased reduction of NADP		 CTD PMID:17329238 PMID:19013440 PMID:21910479 PMID:23295224 PMID:23295227 NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 multiple interactions ISO [AKR1C1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1C1 protein results in increased reduction of cyclopentanone] CTD PMID:21910479 PMID:23261716 NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 multiple interactions ISO [AKR1C2 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone; NADP inhibits the reaction [AKR1C2 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C2 protein results in increased reduction of cyclopentanone]; Ursodeoxycholic Acid inhibits the reaction [[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone] CTD PMID:14672942 PMID:21910479 PMID:23261716 NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 multiple interactions ISO [AKR1C3 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; NADP inhibits the reaction [AKR1C3 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C3 protein results in increased reduction of cyclopentanone] CTD PMID:14672942 PMID:21910479 PMID:23261716 NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873 		JBrowse link
G Akr1d1 aldo-keto reductase family 1, member D1 multiple interactions ISO [AKR1D1 protein co-treated with NADP] results in increased reduction of 7 alpha-hydroxy-4-cholesten-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Aldosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of cholest-4-en-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Corticosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Cortisone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Testosterone CTD PMID:25500266 NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372 		JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Superoxides; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Superoxides; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes CTD PMID:21910479 NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909 		JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 multiple interactions ISO [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione CTD PMID:21910479 NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394 		JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member multiple interactions ISO 1-benzylimidazole inhibits the reaction [NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein]]; NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein] CTD PMID:9585485 NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521 		JBrowse link
G Aldh3a1 aldehyde dehydrogenase 3 family, member A1 multiple interactions
increases activity		 ISO [ALDH3A1 protein co-treated with NADP] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NADP] results in increased oxidation of benzaldehyde
NADP results in increased activity of ALDH3A1 protein		 CTD PMID:10856427 PMID:21256123 NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681 		JBrowse link
G Atg5 autophagy related 5 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of ATG5 protein] CTD PMID:32057834 NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209 		JBrowse link
G Bche butyrylcholinesterase multiple interactions ISO [diphenylcresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tert-butylphenyl diphenyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tri-o-cresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; naringenin inhibits the reaction [[Tritolyl Phosphates co-treated with NADP] results in decreased activity of BCHE protein] CTD PMID:23085349 NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148 		JBrowse link
G Becn1 beclin 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of BECN1 protein] CTD PMID:32057834 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742 		JBrowse link
G Cat catalase multiple interactions EXP CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein] CTD PMID:24713513 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [Genistein co-treated with NADP] binds to CBR1 protein; [Quercetin co-treated with NADP] binds to CBR1 protein; [Triclosan co-treated with NADP] binds to CBR1 protein; Curcumin inhibits the reaction [NADP metabolite binds to and results in increased activity of CBR1 protein]; NADP binds to and results in increased activity of CBR1 protein; NADP metabolite binds to and results in increased activity of CBR1 protein CTD PMID:21910479 PMID:25526675 PMID:25541467 NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393 		JBrowse link
G Cbr3 carbonyl reductase 3 multiple interactions ISO NADP binds to and results in increased activity of CBR3 protein CTD PMID:25526675 NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875 		JBrowse link
G Cd38 CD38 molecule multiple interactions ISO CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986 		JBrowse link
G Ctsb cathepsin B multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of CTSB protein] CTD PMID:32057834 NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500 		JBrowse link
G Ctsd cathepsin D multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of CTSD protein] CTD PMID:32057834 NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488 		JBrowse link
G Cyb5a cytochrome b5 type A multiple interactions ISO [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] CTD PMID:22390216 NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535
Ensembl chr18:78,202,342...78,258,535 		JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions ISO CYBB protein promotes the reaction [[Doxorubicin co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:17275678 NCBI chr  X:13,358,101...13,392,570
Ensembl chr  X:13,359,430...13,392,586 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO
EXP		 NADP promotes the reaction [CYP1A1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP1A1 protein		 CTD PMID:15720144 PMID:24713513 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO [CYP1A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with binimetinib] results in decreased activity of CYP1A2 protein; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Enoxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Resveratrol results in decreased activity of CYP1A2 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:7946932 PMID:11714871 PMID:20825217 PMID:24120545 PMID:33728909 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions ISO [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,2',4,6'-tetramethoxystilbene; [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene; alpha-naphthoflavone inhibits the reaction [[CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene]; NADP promotes the reaction [CYP1B1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]; NADP promotes the reaction [CYP1B1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 PMID:16120791 PMID:19463925 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917 		JBrowse link
G Cyp2a1 cytochrome P450, family 2, subfamily a, polypeptide 1 multiple interactions ISO [NADP co-treated with CYP2A13 protein] results in increased oxidation of 2-ethynylnaphthalene; [NADP co-treated with CYP2A13 protein] results in increased oxidation of Phenanthrenes analog; [NADP co-treated with CYP2A13 protein] results in increased oxidation of propargyl ether analog CTD PMID:27137136 NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887 		JBrowse link
G Cyp2a2 cytochrome P450, family 2, subfamily a, polypeptide 2 multiple interactions EXP [CYP2A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine CTD PMID:20825217 NCBI chr 1:82,263,833...82,289,487
Ensembl chr 1:82,263,833...82,289,487 		JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 multiple interactions EXP [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B1 protein CTD PMID:11805216 PMID:16485904 NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052 		JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of N'-nitrosonornicotine; [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B6 protein; [isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein; Mephenytoin inhibits the reaction [[isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein] CTD PMID:11805216 PMID:16485904 PMID:25500267 PMID:32672941 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 multiple interactions ISO [2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein; [CYP2C19 protein co-treated with NADP] results in increased metabolism of Oxymetazoline; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Docosahexaenoic Acids co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Eicosapentaenoic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Linoleic Acid co-treated with NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ticlopidine inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:16978661 PMID:21177487 PMID:24120545 PMID:36332690 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596 		JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 multiple interactions ISO [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:24120545
G Cyp2d2 cytochrome P450, family 2, subfamily d, polypeptide 2 multiple interactions EXP [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein; CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein] CTD PMID:24713513 NCBI chr 7:113,935,138...113,939,209
Ensembl chr 7:113,935,138...113,939,209 		JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 multiple interactions ISO [CYP2D6 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP deficiency inhibits the reaction [notopterol results in decreased activity of CYP2D6 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:20825217 PMID:24120545 PMID:32198085 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO
EXP		 [vinyl carbamate co-treated with NADP] inhibits the reaction [CYP2E1 protein results in decreased methylation of Dimethylnitrosamine]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2E1 protein		 CTD PMID:11181492 PMID:24713513 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023 		JBrowse link
G Cyp2j4 cytochrome P450, family 2, subfamily j, polypeptide 4 multiple interactions ISO NADP promotes the reaction [azelnidipine results in decreased activity of CYP2J2 protein]; NADP promotes the reaction [Felodipine results in decreased activity of CYP2J2 protein] CTD PMID:30965050 NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions EXP
ISO		 [CYP3A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine
[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone; [[CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 1,4-dihydroxy-2-nonene; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone; [CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of and results in increased oxidation of 4-hydroxy-2-nonenal; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [NADP co-treated with CYP3A4 protein] results in increased activity of imidacloprid analog; [NADP co-treated with CYP3A4 protein] results in increased activity of Thiamethoxam; [retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; Dextromethorphan inhibits the reaction [[retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ketoconazole inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine]; Protons inhibits the reaction [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]		 CTD PMID:16153789 PMID:19818743 PMID:20825217 PMID:21766881 PMID:22390216 More... NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 multiple interactions EXP [CYP3A23-3A1 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine CTD PMID:20825217 NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030 		JBrowse link
G Cyp3a62 cytochrome P450, family 3, subfamily a, polypeptide 62 multiple interactions EXP [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP3A62 protein CTD PMID:24713513 NCBI chr12:16,397,998...16,433,833
Ensembl chr12:16,397,998...16,433,833 		JBrowse link
G Dcxr dicarbonyl and L-xylulose reductase multiple interactions ISO [2,6-dimethyl-1,4-benzoquinone co-treated with NADP] binds to DCXR protein; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [DCXR protein co-treated with NADP] results in increased reduction of Diacetyl; [DCXR protein co-treated with NADP] results in increased reduction of Xylulose; [Disulfiram co-treated with NADP] binds to DCXR protein; [Vitamin K 3 co-treated with NADP] binds to DCXR protein; Butyric Acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; Heptanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; hexanoic acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; NADP binds to and results in increased activity of DCXR protein; Pentanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl] CTD PMID:21910479 PMID:25526675 PMID:28595002 NCBI chr10:106,006,404...106,008,293 JBrowse link
G Decr1 2,4-dienoyl-CoA reductase 1 multiple interactions ISO NADP binds to and results in increased activity of DECR1 protein CTD PMID:25526675 NCBI chr 5:29,411,172...29,439,054
Ensembl chr 5:29,411,172...29,439,018 		JBrowse link
G Decr2 2,4-dienoyl-CoA reductase 2 multiple interactions ISO NADP binds to and results in increased activity of DECR2 protein CTD PMID:25526675 NCBI chr10:15,104,907...15,113,281
Ensembl chr10:15,002,926...15,118,479 		JBrowse link
G Dhfr dihydrofolate reductase decreases activity ISO NADP analog results in decreased activity of DHFR protein CTD PMID:22954684 NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713 		JBrowse link
G Dhrs1 dehydrogenase/reductase 1 multiple interactions ISO NADP binds to and results in increased activity of DHRS1 protein CTD PMID:25526675 NCBI chr15:29,236,522...29,243,807
Ensembl chr15:29,236,522...29,243,838 		JBrowse link
G Dhrs11 dehydrogenase/reductase 11 multiple interactions ISO NADP binds to and results in increased activity of DHRS11 protein CTD PMID:25526675 NCBI chr10:69,698,214...69,708,294
Ensembl chr10:69,698,214...69,708,295 		JBrowse link
G Dhrs13 dehydrogenase/reductase 13 multiple interactions ISO NADP binds to and results in increased activity of DHRS13 protein CTD PMID:25526675 NCBI chr10:62,920,791...62,925,952 JBrowse link
G Dhrs2 dehydrogenase/reductase 2 multiple interactions ISO [NADP co-treated with DHRS2 protein] affects the metabolism of 1-phenyl-1,2-propanedione; [NADP co-treated with DHRS2 protein] affects the metabolism of diethylglyoxime; [NADP co-treated with DHRS2 protein] affects the metabolism of Ketones; NADP binds to and results in increased activity of DHRS2 protein CTD PMID:16685466 PMID:25526675 NCBI chr15:28,688,881...28,703,646
Ensembl chr15:28,688,940...28,703,644 		JBrowse link
G Dhrs3 dehydrogenase/reductase 3 multiple interactions
increases activity		 ISO NADP binds to and results in increased activity of DHRS3 protein
NADP results in increased activity of DHRS3 protein		 CTD PMID:25451588 PMID:25526675 NCBI chr 5:156,747,939...156,782,420
Ensembl chr 5:156,747,962...156,782,417 		JBrowse link
G Dhrs4 dehydrogenase/reductase 4 multiple interactions ISO NADP binds to and results in increased activity of DHRS4 protein CTD PMID:25526675 NCBI chr15:28,966,544...28,978,135
Ensembl chr15:28,966,553...28,978,127 		JBrowse link
G Dhrs7 dehydrogenase/reductase 7 multiple interactions ISO NADP binds to and results in increased activity of DHRS7 protein CTD PMID:25526675 NCBI chr 6:91,332,259...91,347,856
Ensembl chr 6:91,251,323...91,347,892 		JBrowse link
G Dhrs7b dehydrogenase/reductase 7B multiple interactions ISO NADP binds to and results in increased activity of DHRS7B protein CTD PMID:25526675 NCBI chr10:45,504,344...45,537,094
Ensembl chr10:45,504,426...45,537,076 		JBrowse link
G Dhrs7c dehydrogenase/reductase 7C multiple interactions ISO NADP binds to and results in increased activity of DHRS7C protein CTD PMID:25526675 NCBI chr10:52,495,262...52,513,338
Ensembl chr10:52,495,262...52,513,338 		JBrowse link
G Far1 fatty acyl CoA reductase 1 multiple interactions ISO NADP binds to and results in increased activity of FAR1 protein CTD PMID:25526675 NCBI chr 1:167,644,622...167,705,868
Ensembl chr 1:167,644,677...167,705,730 		JBrowse link
G Far2 fatty acyl CoA reductase 2 multiple interactions ISO NADP binds to and results in increased activity of FAR2 protein CTD PMID:25526675 NCBI chr 4:180,973,968...181,087,862
Ensembl chr 4:181,007,622...181,087,255 		JBrowse link
G Faslg Fas ligand multiple interactions ISO CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215 		JBrowse link
G Fasn fatty acid synthase multiple interactions ISO NADP binds to and results in increased activity of FASN protein CTD PMID:25526675 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261 		JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO
EXP		 [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-aminophenol; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoro-N-methylaniline metabolite; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoroaniline; [[FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline
[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline; Methimazole inhibits the reaction [[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol]		 CTD PMID:20369854 NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647 		JBrowse link
G G6pd glucose-6-phosphate dehydrogenase increases reduction
increases expression		 ISO
EXP		 G6PD protein results in increased reduction of NADP
NADP results in increased expression of G6PD protein		 CTD PMID:1922005 PMID:5432368 NCBI chr  X:152,201,081...152,220,863
Ensembl chr  X:152,201,098...152,220,801 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase multiple interactions ISO NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] CTD PMID:15788719 NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235 		JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of GFAP protein] CTD PMID:32057834 NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589 		JBrowse link
G Gfus GDP-L-fucose synthase multiple interactions ISO NADP binds to and results in increased activity of GFUS protein CTD PMID:25526675 NCBI chr 7:107,612,087...107,617,005
Ensembl chr 7:107,612,094...107,616,948 		JBrowse link
G Glud1 glutamate dehydrogenase 1 multiple interactions ISO [GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]; dipicolinic acid inhibits the reaction [[GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]] CTD PMID:26639393 NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957 		JBrowse link
G Gmds GDP-mannose 4, 6-dehydratase multiple interactions ISO NADP binds to and results in increased activity of GMDS protein CTD PMID:25526675 NCBI chr17:32,095,315...32,621,975
Ensembl chr17:32,095,386...32,621,961 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta increases abundance ISO GSK3B protein mutant form results in increased abundance of NADP metabolite CTD PMID:25246272 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions
increases oxidation		 ISO
EXP		 NADP affects the reaction [benzyl isothiocyanate results in decreased activity of GSR protein]; NADP affects the reaction [Carmustine results in decreased activity of GSR protein]
GSR protein results in increased oxidation of NADP
caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]]; Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]
Acetylcysteine inhibits the reaction [arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]]; arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]; Potassium Dichromate promotes the reaction [GSR protein results in increased oxidation of NADP]		 CTD PMID:17937621 PMID:19167472 PMID:19668867 PMID:22036979 PMID:24634002 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions
increases reduction
increases oxidation		 ISO
EXP		 NADP binds to and results in increased activity of HSD11B1 protein
HSD11B1 protein results in increased reduction of NADP
Ziram inhibits the reaction [HSD11B1 protein results in increased oxidation of NADP]		 CTD PMID:25526675 PMID:26859423 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687 		JBrowse link
G Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 multiple interactions ISO NADP binds to and results in increased activity of HSD11B2 protein CTD PMID:25526675 NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899 		JBrowse link
G Hsd17b1 hydroxysteroid (17-beta) dehydrogenase 1 multiple interactions ISO [HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone; coumarin analog inhibits the reaction [[HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone]; NADP binds to and results in increased activity of HSD17B1 protein CTD PMID:21232530 PMID:25526675 NCBI chr10:86,009,728...86,011,928
Ensembl chr10:86,009,728...86,011,927 		JBrowse link
G Hsd17b12 hydroxysteroid (17-beta) dehydrogenase 12 multiple interactions ISO NADP binds to and results in increased activity of HSD17B12 protein CTD PMID:25526675 NCBI chr 3:79,990,048...80,113,556
Ensembl chr 3:79,990,056...80,113,617 		JBrowse link
G Hsd17b3 hydroxysteroid (17-beta) dehydrogenase 3 multiple interactions EXP
ISO		 NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]
NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]; NADP binds to and results in increased activity of HSD17B3 protein		 CTD PMID:20522127 PMID:25526675 NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554 		JBrowse link
G Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 multiple interactions ISO NADP binds to and results in increased activity of HSD17B7 protein CTD PMID:25526675 NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017 		JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 multiple interactions ISO NADP binds to and results in increased activity of HSD17B8 protein CTD PMID:25526675 NCBI chr20:4,826,725...4,828,742
Ensembl chr20:4,822,026...4,828,742 		JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions ISO [Carbenoxolone co-treated with NADP] binds to HSD3B1 protein; [Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein; [Vitamin K 3 co-treated with NADP] binds to HSD3B1 protein CTD PMID:25526675 NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999 		JBrowse link
G Hsdl1 hydroxysteroid dehydrogenase like 1 multiple interactions ISO NADP binds to and results in increased activity of HSDL1 protein CTD PMID:25526675 NCBI chr19:47,615,794...47,631,892
Ensembl chr19:47,615,796...47,631,846 		JBrowse link
G Hsdl2 hydroxysteroid dehydrogenase like 2 multiple interactions ISO [22-hydroxycholesterol co-treated with NADP] binds to HSDL2 protein; [decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; [Estradiol co-treated with NADP] binds to HSDL2 protein; [lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; NADP binds to and results in increased activity of HSDL2 protein CTD PMID:25526675 NCBI chr 5:74,443,933...74,479,104
Ensembl chr 5:74,443,872...74,479,839 		JBrowse link
G Htatip2 HIV-1 Tat interactive protein 2 multiple interactions ISO NADP binds to and results in increased activity of HTATIP2 protein CTD PMID:25526675 NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629 		JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions		 ISO IDH2 protein mutant form results in increased abundance of NADP
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NADP]		 CTD PMID:27469509 NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025 		JBrowse link
G Ins1 insulin 1 multiple interactions EXP [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:20457604 NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536 		JBrowse link
G Iyd iodotyrosine deiodinase increases oxidation ISO IYD protein results in increased oxidation of NADP CTD PMID:33352258 NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319 		JBrowse link
G Kcnab2 potassium voltage-gated channel subfamily A regulatory beta subunit 2 affects binding
multiple interactions		 EXP NADP binds to KCNAB2 protein
[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxycyclopentenone)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxyisoprostane-E2)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-arachidonyl-3-phosphorylcholine metabolite		 CTD PMID:19013139 PMID:21296056 NCBI chr 5:162,899,511...162,988,057
Ensembl chr 5:162,901,896...162,988,243 		JBrowse link
G Kdsr 3-ketodihydrosphingosine reductase multiple interactions ISO NADP binds to and results in increased activity of KDSR protein CTD PMID:25526675 NCBI chr13:22,862,117...22,894,118
Ensembl chr13:22,862,117...22,894,108 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 affects abundance ISO KEAP1 protein affects the abundance of NADP CTD PMID:21775727 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862 		JBrowse link
G Lamp1 lysosomal-associated membrane protein 1 multiple interactions ISO NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]] CTD PMID:33359019 NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of MAP1LC3B protein modified form] CTD PMID:32057834 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Mat2b methionine adenosyltransferase 2 non-catalytic beta subunit multiple interactions ISO [resveratrol co-treated with NADP] binds to MAT2B protein; NADP binds to and results in increased activity of MAT2B protein CTD PMID:25526675 NCBI chr10:25,106,928...25,122,982
Ensembl chr10:25,106,930...25,122,777 		JBrowse link
G Nadk NAD kinase multiple interactions ISO [3-(1-deoxyribofuranosyl)benzamide results in decreased activity of NADK protein] which results in decreased abundance of NADP CTD PMID:22954684 NCBI chr 5:166,145,708...166,176,328
Ensembl chr 5:166,145,481...166,176,322 		JBrowse link
G Nat1 N-acetyltransferase 1 multiple interactions ISO [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr16:22,218,217...22,238,516
Ensembl chr16:22,208,194...22,238,520 		JBrowse link
G Nat2 N-acetyltransferase 2 multiple interactions ISO [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] CTD PMID:20545351 NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 affects abundance
affects oxidation		 ISO NFE2L2 protein affects the abundance of NADP
NFE2L2 protein affects the oxidation of NADP		 CTD PMID:21775727 PMID:29950142 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nmral1 NmrA like redox sensor 1 multiple interactions ISO [Niflumic Acid co-treated with NADP] binds to NMRAL1 protein; [Triclosan co-treated with NADP] binds to NMRAL1 protein; NADP binds to and results in increased activity of NMRAL1 protein CTD PMID:25526675 NCBI chr10:10,841,693...10,850,199
Ensembl chr10:10,841,799...10,850,192 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO
EXP		 [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes
NADP promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3]		 CTD PMID:20545351 PMID:21910479 PMID:27558805 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Nsdhl NAD(P) dependent steroid dehydrogenase-like multiple interactions ISO NADP binds to and results in increased activity of NSDHL protein CTD PMID:25526675 NCBI chr  X:150,775,034...150,807,161
Ensembl chr  X:150,775,080...150,807,142 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP] CTD PMID:17669606 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pecr peroxisomal trans-2-enoyl-CoA reductase multiple interactions ISO [Acyl Coenzyme A co-treated with NADP] binds to PECR protein; [decanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [lauroyl-coenzyme A co-treated with NADP] binds to PECR protein; NADP binds to and results in increased activity of PECR protein CTD PMID:25526675 NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511 		JBrowse link
G Pgd phosphogluconate dehydrogenase increases expression EXP NADP results in increased expression of PGD protein CTD PMID:1922005 NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778 		JBrowse link
G Por cytochrome p450 oxidoreductase multiple interactions
increases metabolic processing		 EXP
ISO		 NADP affects the reaction [POR protein affects the metabolism of Nitrofurantoin]; NADP promotes the reaction [POR protein results in increased reduction of Vitamin K 3]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP
diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP; [POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [POR protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [POR protein co-treated with NADP] results in increased chemical synthesis of Hydrogen Peroxide; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of Oxygen]; NADP promotes the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of Oxygen]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]		 CTD PMID:18206659 PMID:20545351 PMID:20561902 PMID:21215309 PMID:22390216 More... NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245 		JBrowse link
G Ppif peptidylprolyl isomerase F multiple interactions EXP [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein] CTD PMID:26975474 NCBI chr16:1,257,197...1,263,919
Ensembl chr16:1,257,106...1,263,913 		JBrowse link
G Prnp prion protein multiple interactions ISO [NADP co-treated with cupric chloride] promotes the reaction [PRNP protein binds to PRNP protein]
[Copper co-treated with NADP] promotes the reaction [PRNP protein binds to PRNP protein]; [Copper co-treated with NADP] results in increased susceptibility to [PRNP protein binds to PRNP protein]		 CTD PMID:16990274 PMID:19149680 NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937 		JBrowse link
G Ptgr1 prostaglandin reductase 1 multiple interactions EXP [PTGR1 protein co-treated with NADP] affects the reduction of (2E)-decenal; [PTGR1 protein co-treated with NADP] affects the reduction of 1-pentene-3-one; [PTGR1 protein co-treated with NADP] affects the reduction of 2,4-nonadienal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-butenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-octenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-pentenal; [PTGR1 protein co-treated with NADP] affects the reduction of 3-buten-2-one; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of Acrolein; [PTGR1 protein co-treated with NADP] affects the reduction of benzylideneacetone; [PTGR1 protein co-treated with NADP] affects the reduction of Chalcone; [PTGR1 protein co-treated with NADP] affects the reduction of cinnamaldehyde; [PTGR1 protein co-treated with NADP] results in increased reduction of and results in increased activity of acylfulvene CTD PMID:11524419 PMID:21939268 NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666 		JBrowse link
G Qdpr quinoid dihydropteridine reductase multiple interactions ISO NADP binds to and results in increased activity of QDPR protein CTD PMID:25526675 NCBI chr14:65,670,251...65,683,853
Ensembl chr14:65,670,131...65,683,854 		JBrowse link
G Rdh11 retinol dehydrogenase 11 multiple interactions ISO NADP binds to and results in increased activity of RDH11 protein CTD PMID:25526675 NCBI chr 6:97,979,377...97,995,252
Ensembl chr 6:97,979,378...97,995,252 		JBrowse link
G Rdh12 retinol dehydrogenase 12 multiple interactions ISO NADP binds to and results in increased activity of RDH12 protein CTD PMID:25526675 NCBI chr 6:98,015,465...98,028,388
Ensembl chr 6:98,015,465...98,028,388 		JBrowse link
G Rdh13 retinol dehydrogenase 13 multiple interactions ISO NADP binds to and results in increased activity of RDH13 protein CTD PMID:25526675 NCBI chr 1:69,373,014...69,401,454
Ensembl chr 1:69,373,113...69,400,908 		JBrowse link
G Rdh14 retinol dehydrogenase 14 multiple interactions ISO NADP binds to and results in increased activity of RDH14 protein CTD PMID:25526675 NCBI chr 6:33,156,569...33,161,712
Ensembl chr 6:33,156,569...33,161,712 		JBrowse link
G Rdh8 retinol dehydrogenase 8 multiple interactions ISO NADP binds to and results in increased activity of RDH8 protein CTD PMID:25526675 NCBI chr 8:19,353,191...19,360,462
Ensembl chr 8:19,353,191...19,360,462 		JBrowse link
G Sdr39u1 short chain dehydrogenase/reductase family 39U, member 1 multiple interactions ISO NADP binds to and results in increased activity of SDR39U1 protein CTD PMID:25526675 NCBI chr15:29,378,156...29,380,989
Ensembl chr15:29,378,026...29,381,560 		JBrowse link
G Sdr42e1 short chain dehydrogenase/reductase family 42E, member 1 multiple interactions ISO NADP binds to and results in increased activity of SDR42E1 protein CTD PMID:25526675 NCBI chr19:45,715,366...45,727,901
Ensembl chr19:45,715,399...45,727,901 		JBrowse link
G Spr sepiapterin reductase multiple interactions ISO NADP binds to and results in increased activity of SPR protein CTD PMID:25526675 NCBI chr 4:117,671,948...117,676,292
Ensembl chr 4:117,671,949...117,675,678 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in decreased expression of SQSTM1 protein] CTD PMID:32057834 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 multiple interactions ISO [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562 		JBrowse link
G Taldo1 transaldolase 1 decreases abundance
multiple interactions		 ISO TALDO1 gene mutant form results in decreased abundance of NADP
Acetylcysteine inhibits the reaction [TALDO1 gene mutant form results in decreased abundance of NADP]		 CTD PMID:19436114 NCBI chr 1:196,493,634...196,503,965
Ensembl chr 1:196,493,589...196,503,974 		JBrowse link
G Tdo2 tryptophan 2,3-dioxygenase affects abundance EXP TDO2 protein affects the abundance of NADP CTD PMID:7306070 NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511 		JBrowse link
G Tigar TP53 induced glycolysis regulatory phosphatase multiple interactions
increases abundance		 EXP
ISO		 NADP inhibits the reaction [Kainic Acid results in decreased expression of TIGAR protein]
TIGAR protein results in increased abundance of NADP
NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]		 CTD PMID:32057834 PMID:33359019 NCBI chr 4:159,927,136...159,946,077
Ensembl chr 4:159,927,139...159,946,029 		JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO NADP promotes the reaction [sodium bichromate results in increased expression of TP53 protein] CTD PMID:10942736 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Txn1 thioredoxin 1 multiple interactions EXP [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:20457604 NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629 		JBrowse link
G Txnrd1 thioredoxin reductase 1 multiple interactions
increases reduction		 ISO
EXP		 [NADP co-treated with Mechlorethamine] results in decreased activity of TXNRD1 protein; NADP affects the reaction [benzyl isothiocyanate results in decreased activity of TXNRD1 protein]
NADP results in increased reduction of TXNRD1 protein
[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein; [NADP co-treated with Mechlorethamine] promotes the reaction [TXNRD1 protein binds to TXNRD1 protein]; [NADP co-treated with Mechlorethamine] results in decreased activity of and results in increased alkylation of TXNRD1 protein; [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; [Sodium Selenite co-treated with NADP] inhibits the reaction [Mercuric Chloride results in decreased activity of TXNRD1 protein]; [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; [TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein]; Auranofin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dinitrochlorobenzene promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dithionitrobenzoic Acid inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; formic acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Glutathione inhibits the reaction [[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; NADP affects the reaction [Arsenic Trioxide results in decreased activity of TXNRD1 protein]; Oxygen deficiency inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Pentetic Acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Sodium Selenite inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]		 CTD PMID:17640917 PMID:17937621 PMID:20457604 PMID:20810785 PMID:22694104 More... NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863 		JBrowse link
G Wwox WW domain-containing oxidoreductase multiple interactions ISO NADP binds to and results in increased activity of WWOX protein CTD PMID:25526675 NCBI chr19:42,432,141...43,360,278
Ensembl chr19:42,432,152...43,359,391 		JBrowse link
nicotinic acid-adenine dinucleotide phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cd38 CD38 molecule multiple interactions ISO CD38 gene mutant form inhibits the reaction [FASL protein results in increased abundance of NAADP]; CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986 		JBrowse link
G Edn1 endothelin 1 increases metabolic processing
multiple interactions		 ISO EDN1 protein results in increased metabolism of NAADP
NOX1 mutant form inhibits the reaction [EDN1 protein results in increased metabolism of NAADP]		 CTD PMID:23940720 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885 		JBrowse link
G Faslg Fas ligand multiple interactions
increases abundance		 ISO CD38 gene mutant form inhibits the reaction [FASL protein results in increased abundance of NAADP]; CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215 		JBrowse link
G Mcoln1 mucolipin TRP cation channel 1 increases activity
multiple interactions		 ISO NAADP results in increased activity of MCOLN1 protein
[NAADP results in increased activity of MCOLN1 protein] which affects the localization of Calcium		 CTD PMID:21613607 NCBI chr12:1,560,341...1,574,252
Ensembl chr12:1,560,359...1,574,252 		JBrowse link
G Nox1 NADPH oxidase 1 multiple interactions ISO NOX1 mutant form inhibits the reaction [EDN1 protein results in increased metabolism of NAADP] CTD PMID:23940720 NCBI chr  X:97,279,058...97,332,291
Ensembl chr  X:97,279,056...97,302,236 		JBrowse link
NMN zwitterion term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acadm acyl-CoA dehydrogenase medium chain multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of ACADM mRNA] CTD PMID:23834033 NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147 		JBrowse link
G Acp5 acid phosphatase 5, tartrate resistant multiple interactions EXP Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of ACP5 protein] CTD PMID:30292833 NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] CTD PMID:34752167 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554 		JBrowse link
G Aldoc aldolase, fructose-bisphosphate C multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in decreased expression of ALDOA protein] CTD PMID:38159578 NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066 		JBrowse link
G Axin1 axin 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in increased expression of AXIN1 protein] CTD PMID:32005247 NCBI chr10:15,163,477...15,215,615
Ensembl chr10:15,163,684...15,215,615 		JBrowse link
G Bglap bone gamma-carboxyglutamate protein multiple interactions EXP
ISO		 Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in decreased activity of BGLAP protein]; Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in decreased expression of BGLAP protein] CTD PMID:30292833 NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495 		JBrowse link
G Casp1 caspase 1 multiple interactions ISO
EXP		 Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of CASP1 protein modified form] CTD PMID:30292833 NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383 		JBrowse link
G Cat catalase multiple interactions ISO [Nicotinamide Mononucleotide co-treated with Zearalenone] results in decreased expression of CAT protein CTD PMID:38159578 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CCND1 protein]; Nicotinamide Mononucleotide inhibits the reaction [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased expression of CCND1 protein] CTD PMID:32005247 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Cd36 CD36 molecule multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of CD36 mRNA] CTD PMID:38159578 NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903 		JBrowse link
G Cd38 CD38 molecule multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of CD38 mRNA] CTD PMID:38159578 NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A protein]]; Dicumarol inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A protein]]; Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A protein] CTD PMID:37640247 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN2A protein]]; Dicumarol inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN2A protein]]; Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN2A protein] CTD PMID:37640247 NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149 		JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] CTD PMID:34752167 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624 		JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of CPT1A mRNA] CTD PMID:38159578 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CTNNB1 protein]; Nicotinamide Mononucleotide inhibits the reaction [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased expression of CTNNB1 protein] CTD PMID:32005247 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Dgat1 diacylglycerol O-acyltransferase 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of DGAT1 mRNA] CTD PMID:38159578 NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299 		JBrowse link
G Dgat2 diacylglycerol O-acyltransferase 2 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of DGAT2 mRNA] CTD PMID:38159578 NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428 		JBrowse link
G Elovl3 ELOVL fatty acid elongase 3 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of ELOVL3 mRNA] CTD PMID:38159578 NCBI chr 1:244,997,287...245,001,115
Ensembl chr 1:244,997,287...245,001,115 		JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor decreases abundance ISO ERCC6 gene mutant form results in decreased abundance of Nicotinamide Mononucleotide CTD PMID:25440059 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587 		JBrowse link
G Fasn fatty acid synthase multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of FASN mRNA] CTD PMID:38159578 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261 		JBrowse link
G Foxo4 forkhead box O4 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of FOXO4 mRNA] CTD PMID:36336710 NCBI chr  X:66,385,241...66,392,115
Ensembl chr  X:66,385,558...66,392,115 		JBrowse link
G Galnt1 polypeptide N-acetylgalactosaminyltransferase 1 increases expression ISO Nicotinamide Mononucleotide results in increased expression of GALNT1 mRNA CTD PMID:29935245 NCBI chr18:15,489,015...15,568,849
Ensembl chr18:15,489,020...15,568,245 		JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions ISO [resveratrol co-treated with Nicotinamide Mononucleotide] inhibits the reaction [RETN protein results in increased activity of GLB1 protein] CTD PMID:23827175 NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein] CTD PMID:34752167 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of H2AX protein] CTD PMID:36756972 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 		JBrowse link
G Il18 interleukin 18 multiple interactions ISO
EXP		 Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of IL18 protein]; Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of IL18 mRNA] CTD PMID:30292833 PMID:38159578 NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO
EXP		 Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of IL1B protein]; Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of IL1B mRNA] CTD PMID:30292833 PMID:38159578 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Lpin1 lipin 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of LPIN1 protein] CTD PMID:38159578 NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased phosphorylation of MAPK1 protein] CTD PMID:38159578 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased phosphorylation of MAPK3 protein] CTD PMID:38159578 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mir34a microRNA 34a multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of ACADM mRNA]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARA mRNA]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARD mRNA] CTD PMID:23834033 NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103 		JBrowse link
G Nampt nicotinamide phosphoribosyltransferase affects binding
multiple interactions		 EXP
ISO		 NAMPT protein binds to Nicotinamide Mononucleotide
Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CCND1 protein]; Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CTNNB1 protein]
Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]		 CTD PMID:16901503 PMID:23834033 PMID:32005247 NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100 		JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions ISO
EXP		 Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of NLRP3 protein]
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of NLRP3 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of NLRP3 protein]		 CTD PMID:30292833 NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811 		JBrowse link
G Nnt nicotinamide nucleotide transhydrogenase multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein]]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of FOXO4 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of PPARGC1A mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of SHANK2 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein] CTD PMID:36336710 NCBI chr 2:51,411,413...51,505,125
Ensembl chr 2:51,411,413...51,504,823 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression
multiple interactions		 ISO Nicotinamide Mononucleotide results in increased expression of NQO1 protein
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide results in increased expression of NQO1 protein]		 CTD PMID:37640247 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 affects abundance
multiple interactions		 ISO PARP1 protein affects the abundance of Nicotinamide Mononucleotide
[Nicotinamide Mononucleotide co-treated with Cisplatin] results in decreased expression of PARP1 protein; Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of PARP1 mRNA]		 CTD PMID:19426698 PMID:34089817 PMID:38159578 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pgk1 phosphoglycerate kinase 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in decreased expression of PGK1 protein] CTD PMID:38159578 NCBI chr  X:71,271,454...71,287,429
Ensembl chr  X:71,271,440...71,287,418 		JBrowse link
G Pnpla2 patatin-like phospholipase domain containing 2 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of PNPLA2 protein] CTD PMID:38159578 NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARA mRNA] CTD PMID:23834033 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Ppard peroxisome proliferator-activated receptor delta multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARD mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of PPARD mRNA] CTD PMID:23834033 PMID:38159578 NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of PPARG mRNA] CTD PMID:38159578 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of PPARGC1A mRNA] CTD PMID:36336710 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656 		JBrowse link
G Pycard PYD and CARD domain containing multiple interactions EXP Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of PYCARD protein] CTD PMID:30292833 NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955 		JBrowse link
G Retn resistin multiple interactions ISO [resveratrol co-treated with Nicotinamide Mononucleotide] inhibits the reaction [RETN protein results in increased activity of GLB1 protein] CTD PMID:23827175 NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620 		JBrowse link
G Scd stearoyl-CoA desaturase multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of SCD1 mRNA] CTD PMID:38159578 NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562 		JBrowse link
G Shank2 SH3 and multiple ankyrin repeat domains 2 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of SHANK2 mRNA] CTD PMID:36336710 NCBI chr 1:199,146,210...199,590,962
Ensembl chr 1:199,169,429...199,589,394 		JBrowse link
G Sirt1 sirtuin 1 increases expression
multiple interactions		 EXP
ISO		 Nicotinamide Mononucleotide results in increased expression of SIRT1 mRNA
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of SIRT1 mRNA]
Nicotinamide Mononucleotide inhibits the reaction [Ethanol results in decreased expression of SIRT1 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Ethanol results in decreased expression of SIRT1 protein]		 CTD PMID:32087266 PMID:38159578 NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260 		JBrowse link
G Slc12a8 solute carrier family 12, member 8 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in decreased expression of SLC12A8 mRNA] CTD PMID:38159578 NCBI chr11:67,116,876...67,266,548
Ensembl chr11:67,116,877...67,266,834 		JBrowse link
G Slc47a1 solute carrier family 47 member 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] CTD PMID:22419765 NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637 		JBrowse link
G Slc47a2 solute carrier family 47 member 2 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] CTD PMID:22419765 NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904 		JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in decreased expression of SOD1 protein] CTD PMID:38159578 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO [Nicotinamide Mononucleotide co-treated with Zearalenone] results in decreased expression of SOD2 mRNA CTD PMID:38159578 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein]]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein] CTD PMID:36336710 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] CTD PMID:34752167 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of TNF mRNA] CTD PMID:38159578 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Txnip thioredoxin interacting protein multiple interactions ISO
EXP		 Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of TXNIP protein]
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of TXNIP mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of TXNIP protein]		 CTD PMID:30292833 NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886 		JBrowse link
G Ucp2 uncoupling protein 2 multiple interactions EXP
ISO		 Nicotinamide Mononucleotide inhibits the reaction [Ethanol results in increased expression of UCP2 protein]
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of UCP2 mRNA]		 CTD PMID:32087266 PMID:38159578 NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19932
    chemical entity 19930
      atom 19930
        nonmetal atom 19859
          nitrogen atom 19024
            nitrogen molecular entity 19024
              organonitrogen compound 18871
                organonitrogen heterocyclic compound 18179
                  pyridines 11530
                    pyridine nucleotide 234
                      1-(5-O-phosphono-beta-D-ribofuranosyl)-5-(sulfanylcarbonyl)pyridinium-3-carbonyl adenylate 0
                      1-(5-O-phosphono-beta-D-ribofuranosyl)pyridin-4(1H)-one 0
                      5-carboxy-1-(5-O-phosphono-beta-D-ribofuranosyl)pyridinium-3-carbonyl adenylate 0
                      Ni(II)-pyridinium-3,5-bisthiocarboxylic acid mononucleotide 0
                      nicotinamide nucleotide + 234
                      nicotinic acid nucleotide + 94
                      pyridinium-3,5-biscarboxylic acid mononucleotide + 0
                      pyridinium-3,5-bisthiocarboxylic acid mononucleotide 0
                      pyridinium-3-carboxy-5-thiocarboxylic acid mononucleotide 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19932
    subatomic particle 19930
      composite particle 19930
        hadron 19930
          baryon 19930
            nucleon 19930
              atomic nucleus 19930
                atom 19930
                  main group element atom 19876
                    p-block element atom 19876
                      chalcogen 19624
                        oxygen atom 19594
                          oxygen molecular entity 19594
                            hydroxides 19394
                              oxoacid 18815
                                pnictogen oxoacid 14986
                                  phosphorus oxoacid 14583
                                    phosphoric acids 13926
                                      phosphoric acid 13926
                                        phosphoric acid derivative 13832
                                          phosphate 13831
                                            organic phosphate 13831
                                              nucleoside phosphate 1865
                                                nucleotide 1862
                                                  pyridine nucleotide 234
                                                    1-(5-O-phosphono-beta-D-ribofuranosyl)-5-(sulfanylcarbonyl)pyridinium-3-carbonyl adenylate 0
                                                    1-(5-O-phosphono-beta-D-ribofuranosyl)pyridin-4(1H)-one 0
                                                    5-carboxy-1-(5-O-phosphono-beta-D-ribofuranosyl)pyridinium-3-carbonyl adenylate 0
                                                    Ni(II)-pyridinium-3,5-bisthiocarboxylic acid mononucleotide 0
                                                    nicotinamide nucleotide + 234
                                                    nicotinic acid nucleotide + 94
                                                    pyridinium-3,5-biscarboxylic acid mononucleotide + 0
                                                    pyridinium-3,5-bisthiocarboxylic acid mononucleotide 0
                                                    pyridinium-3-carboxy-5-thiocarboxylic acid mononucleotide 0
paths to the root